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The distribution of copper, zinc and iron in the brain and the implications for 
Alzheimer’s disease 
Abstract 
Metal dyshomeostasis in the brain is an underlying feature of Alzheimer’s disease. The further 
understanding of metal distribution in the brain is critical to further explore the role of metals in AD. The 
specific causes and effects that result in metals influencing the build-up of toxic, insoluble amyloid-beta 
plaques remain ambiguous. Treatment of cannabidiol (CBD) to APPxPS1 mice has been studied to 
prevent social recognition deficit and has the potential for a preventative treatment for Alzheimer’s 
disease (AD). This project analyses the distribution of Cu, Zn and Fe in healthy and affected transgenic 
APPxPS1 mice brains and produces comprehensive metal concentration maps outlining any 
accumulations and/or trends emerging. This project studies how metal distribution is affected when 
transgenic mice with Alzheimer’s and wild-type (WT), healthy mice are treated with cannadibiol. Four 
groups of mice will be studied for comparison consisting of 14 APPxPS1 mice exhibiting AD (7 treated 
with CBD and 7 untreated) and 16 wild-type, healthy mice (8 treated with CBD and 8 untreated). The thirty 
sample mice brains were prepared and cryosectioned and analysed using laser ablation inductively 
coupled plasma mass spectrometry where metal concentrations were quantified using matrix-matched 
standards. Metal distribution maps were created and spatial analysis conducted to compare areas of 
metal deficiency or accumulation between the four groups. The metal concentration maps highlighted 
trends for each metal in the brain, such as Zn enrichment in the corpus callosum. The hippocampus and 
cerebellum are identified as regions with enhanced plaque pathology and average concentrations of 
metals between these regions were compared. These areas can indicate potential regions of increased 
(or decreased) metal activity which could be the result of failed mechanisms to control metal ion 
homeostasis. The comparison of metal concentrations in the whole brain, hippocampus and cerebellum 
of APPxPS1 with AD to WT mice identified a lower average concentration of metals in an AD brain. 
Treatments of CBD to both APPxPS1 mice and WT mice resulted in a higher metal concentration on 
average. Therefore, it is indicated that metals in AD affected brains are deficient and metal-targeting 
treatments, such as metal chelators, could prove to be therapeutic for AD. The treatment of CBD was 
found to increase the average metal concentration in WT brains to much higher levels which could 
potentially lead to toxicity. The findings in this study pave the way for future research to further explore 
metal deficiency in AD and treatments specifically targeting metals. The treatment of CBD can also be 
further explored in both its therapeutic heightening of metal concentrations in an AD brain and its 










Alzheimers disease, metals 




The distribution of copper, zinc and iron in the brain and the 
implications for Alzheimer’s disease 
 
 
A thesis submitted in partial fulfilment of the requirements for the award of the degree 
of 
BACHELOR OF SCIENCE (HONOURS) 
From 














(School of Earth & Environmental Sciences, Faculty of Science, Medicine and Health) (MAY, 
2017) 
The information in this thesis is entirely the result of investigations conducted by the author, 
unless otherwise acknowledged, and has not been submitted in part, or otherwise, for any 
other degree or qualification.  
 
Kaila Tonge 





Metal dyshomeostasis in the brain is an underlying feature of Alzheimer’s disease. The 
further understanding of metal distribution in the brain is critical to further explore the role of 
metals in AD. The specific causes and effects that result in metals influencing the build-up of 
toxic, insoluble amyloid-beta plaques remain ambiguous. Treatment of cannabidiol (CBD) to 
APPxPS1 mice has been studied to prevent social recognition deficit and has the potential for 
a preventative treatment for Alzheimer’s disease (AD). This project analyses the distribution 
of Cu, Zn and Fe in healthy and affected transgenic APPxPS1 mice brains and produces 
comprehensive metal concentration maps outlining any accumulations and/or trends 
emerging. This project studies how metal distribution is affected when transgenic mice with 
Alzheimer’s and wild-type (WT), healthy mice are treated with cannadibiol. Four groups of 
mice will be studied for comparison consisting of 14 APPxPS1 mice exhibiting AD (7 treated 
with CBD and 7 untreated) and 16 wild-type, healthy mice (8 treated with CBD and 8 
untreated). The thirty sample mice brains were prepared and cryosectioned and analysed 
using laser ablation inductively coupled plasma mass spectrometry where metal 
concentrations were quantified using matrix-matched standards. Metal distribution maps were 
created and spatial analysis conducted to compare areas of metal deficiency or accumulation 
between the four groups. The metal concentration maps highlighted trends for each metal in 
the brain, such as Zn enrichment in the corpus callosum. The hippocampus and cerebellum 
are identified as regions with enhanced plaque pathology and average concentrations of 
metals between these regions were compared. These areas can indicate potential regions of 
increased (or decreased) metal activity which could be the result of failed mechanisms to 
control metal ion homeostasis. The comparison of metal concentrations in the whole brain, 
hippocampus and cerebellum of APPxPS1 with AD to WT mice identified a lower average 
concentration of metals in an AD brain. Treatments of CBD to both APPxPS1 mice and WT 
mice resulted in a higher metal concentration on average. Therefore, it is indicated that metals 
in AD affected brains are deficient and metal-targeting treatments, such as metal chelators, 
could prove to be therapeutic for AD. The treatment of CBD was found to increase the 
average metal concentration in WT brains to much higher levels which could potentially lead 
to toxicity. The findings in this study pave the way for future research to further explore 
metal deficiency in AD and treatments specifically targeting metals. The treatment of CBD 
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can also be further explored in both its therapeutic heightening of metal concentrations in an 
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Alzheimer’s disease (AD) is the most common form of dementia and combined they are 
determined to be the second leading underlying cause of death in Australians in 2013 (ABS, 
2016). There is no clear pattern of inheritance therefore age is considered to be the largest 
risk factor for AD where 96% of people identified as having dementia or Alzheimer’s disease 
in 2009 were over the age of 65 (ABS, 2016). Females are more likely to be affected by AD 
with the sex ratio between 2009-2013 being 50 male deaths per 100 female deaths (ABS, 
2016). The disease targets brain function associated with memory, coordination, learning and 
even emotions. It results in a slow decline of movement, speech, memory and basically every 
bodily function we take for granted until another perhaps virus targets the weakened immune 
system and the individual dies. There is currently no cure for AD and understanding of the 
true cause of the disease is still being unlocked. The number of deaths caused by this disease 
rose by 32% between 2009-2013 which creates an alarming socioeconomic problem that 
needs to be addressed as quick and efficiently as possible (ABS, 2016).  
 
Figure 1 - Comparison of normal and diseased brain cell interaction, highlighting amyloid plaque and neurofibrillary 
deposition (BrightFocus Foundation, 2000) 
 
Alzheimer’s disease is characterised by the two main deposits of amyloid plaques and 
neurofibrillary tangles. These deposits hinder a neurotransmitters ability to communicate 
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effectively between neurons across a synapse, which is a connection between brain cells. This 
interrupts healthy brain cell activity and results in cell death. Plaques occur outside the 
neuron and neurofibrillary tangles occur inside the neuron, (Figure 1). Plaques are caused by 
the build-up of the sticky protein: amyloid-beta. This protein normally aggregates into a 
soluble mass in the brain whereas in the formation of plaques it aggregates into a hard, 
insoluble mass that destroys synapses and leads to cell death. The mutation of amyloid 
precursor protein (APP) leads to this characteristic insoluble build-up of amyloid-beta into 
plaques. Amyloid plaque build-up is widely accepted to be a pathological hallmark in AD 
and plaque pathology has shown they are mostly concentrated in the cerebellum, neocortex, 
amygdala and hippocampus (Hardy et al. 2002). 
APPxPS1 mice model exists as a model of AD and exhibit the symptoms, such as memory 
loss, commonly seen in AD (Duncan et al. 2012). The APPxPS1 mice are used in this study 
to act as a model of AD as close as possible to the human brain with AD. These mice 
overexpress the APP to produce a fast-tracked model of AD in a mouse brain. Metals, 
specifically Cu, Fe and Zn, have been studied to interact with amyloid-beta to influence 
fibrillization and toxicity (Tiiman et al. 2013). Copper, Fe and Zn are implicated in AD 
processes but the full understanding of their link with AD is still unknown. Metals are often 
concentrated in areas of increased plaque pathology and it is therefore necessary to further 
understand their interaction with AD processes to unlock deeper understanding of AD itself. 
Therefore, the aim of this project is to investigate whether changes in Cu, Fe and Zn can be 
detected in APPxPS1 mice by comparing them to healthy controls.  
Furthermore, CBD has been proposed as a possible treatment for AD and has been studied to 
prevent social recognition deficit in APPxPS1 mice (Cheng et al. 2014). The treatment of 
CBD to AD affected brains can be studied in regards to metal distribution to further implicate 
metals in AD processes. Another aim of this project is to assess the effect of CBD on metal 
distribution in the brain of APPxPS1 mice and WT mice. To address these aims 30 mice were 
cryosectioned, 14 of which were APPxPS1 mice with AD (7 treated with CBD and 7 
untreated) and 16 of which were WT, healthy mice (7 treated with CBD and 7 untreated). The 
sectioned brains of the 30 mice were analysed using laser ablation inductively coupled 
plasma mass spectrometry (LA ICP-MS). Imaging software was then utilised to quantify the 
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data from intensity (laser counts per second) into comprehensive metal concentration (ppm) 
maps of Cu, Zn and Fe in each brain. Spatial analysis enabled calculation of the average 
metal concentrations in the whole brain, hippocampus and cerebellum. This allowed 
extensive comparison between metal concentration maps and statistical analysis from the data 
extracted using spatial analysis.  
In the first chapter the role of metals in AD will be discussed as well as the role of metals in a 
healthy brain. The use of the LA ICP-MS method is then discussed in regards to its role in 
producing the data necessary for the metal concentration maps. The methodology for sample 
preparation and analysis is then outlined in chapter 2. The results achieved in this study will 
be discussed in chapter 3 for the whole brain, hippocampus and cerebellum for each metal 
(Cu, Fe and Zn). The conclusions deduced from the results will be discussed in Chapter 4. 





CHAPTER 1 – LITERATURE REVIEW 
1.1 METALS IN THE BRAIN 
Metal ions are present in strict quantities in the brain and facilitate many vital processes and 
metal-ion homeostasis is critical for normal brain function. Specifically, Duce et al. (2010) 
recognises metals as the facilitators and key maintenance for ‘enzymatic activities, 
mitochondrial function, myelination, neurotransmission as well as learning and memory’. 
Brain cells have therefore developed mechanisms to maintain metal ion homeostasis. A 
critical spike in metal ion levels can quickly result in neurotoxicity and a drop can result in 
severe deficiencies that cause numerous problems. A study by Ramos et al. (2014) attempted 
to provide a standard for “normal” amounts of metals in the brain using ICP-MS for analysis 
and found that the highest levels of Zn were found in the hippocampus and the highest levels 
of Cu in the putamen. These regions of the brain, especially the hippocampus, are directly 
affected in AD and are intrinsic to memory and motor control. Trace element distribution is 
notoriously heterogeneous in the brain, as supported by Ramos et al. (2014), and the ability to 
provide comparative bio maps of metals will be crucial to further understanding their role in 
AD.  
1.2 OXIDATIVE STRESS AND METAL FUNCTION 
The redox capacity of Cu in the brain is used for a variety of normal brain functions and Bush 
et al. (2003) suggests that this rapid transition of Cu between oxidation states is central to the 
role of Cu in cuproenzyme activity. However, the interrupted metabolism of Cu can result in 
‘excessive free radical production and associated increases in neuronal oxidative stress’ 
(Bush et al. 2003). Therefore, the homeostasis of Cu in the brain is crucial for oxidative 
normality in necessary functions. Bush et al. (2003) also links the associated oxidative stress 
caused by Cu metabolism failure to the role of Cu in its interaction with amyloid beta to form 
plaques. Zinc and Fe are also highly implicated by Bush et al. (2003) and Greenough et al. 
(2013) in the formation of plaques where the highest concentrations of the metals are found 
in regions with enhanced plaque pathology such as the aforementioned neocortex, 
hippocampus and amygdala. The accumulations of Cu, Zn and Fe would be an indicator for a 
mechanism in metal metabolism failing and is therefore necessary to map Cu, Zn and Fe 
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accumulations in the brain to locate possible plaque accumulations and other such areas of 
interest. Figure 2 doedaa  
 
Figure 2 - Example of reactions to form damaging hydroxyl radicals (Khalil et al. 2011) 
 
The neurotoxicity of these oxidised states is also reinforced in Roberts et al. (2012) where the 
production of hydrogen peroxide and generation of hydroxyl radicals by Fenton chemistry are 
implicated. The oxidised forms of Fe or Cu produce hydrogen peroxide when binding 
amyloid-beta proteins due to a reduction of molecular oxygen (Roberts et al. 2012). Figure 2 
displays the Fenton chemistry implicated in Roberts et al. 2012 where hydrogen peroxide and 
reduced Fe or Cu generate hydroxyl radicals. Hydroxyl radicals are extremely hazardous in 
the brain and are characteristic of AD neuropathology. Another mechanism that is potentially 
leading to hydrogen peroxide production is the increase of cytoplasmic Cu (Freedman et al. 
1989).  
Ceruloplasmin is a protein found in plasma that is capable of transporting Cu, has an 
important redox capacity and has also been linked to the metabolism of Fe. Snaedal et al. 
(1998) found that the ceruloplasmin oxidative activity in plasma of AD patients was greatly 
reduced yet the copper concentrations between patients and their controls were not 
significantly different. Bush et al. (2003) found that patients with AD have low ceruloplasmin 
levels as well as lower levels of a copper containing enzyme superoxide dismutase (SOD1). 
Superoxide dismutase is described as being ‘key in suppressing the amounts of superoxide 
anion radicals (Snaedel et al. 1998). The lower levels of SOD1 actually point to a deficiency 
in intracellular Cu rather than an accumulation which further validates the need to not only 
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look for metal accumulation but rather trends of areas with no trace of metals/extremely low 
traces in the bio maps created in this project. The deficiency of Cu implicated in some journal 
articles as compared to highly elevated levels of Cu studied in other journal articles can be 
married through the paper of White et al. (2006). It was found in this paper that extracellular 
Cu levels are elevated in relevance to the areas of the brain most implicated in AD pathology 
whereas subcellular Cu levels can be deficient due to decreased activity of several 
cuproenzymes and low ceruloplasmin in a brain with AD (White et al. 2006). This links in 
with reduced SOD1 levels in AD brains correlated with reduced Cu levels as also found in 
Snaedel et al. (1998). 
1.3 THE ROLE OF METALS IN AD 
The blood brain barrier (BBB) acts as a membrane separating the cerebrospinal fluid (CSF) 
from the blood, and is intrinsic to the movements of metals across it (Duce et al. 2010). The 
non-bound forms of metals such as zinc (Zn), iron (Fe) and copper (Cu) are extremely 
hazardous in the brain and are therefore highly regulated by the BBB. The mechanisms that 
brain cells have developed to keep metal ions at equilibrium after permeating the BBB can be 
disrupted and the chance of neurotoxicity developing and causing such diseases as 
Alzheimer’s increases dramatically. Duce et al. (2010) demonstrates an example of this 
where decreased mitochondrial activity in a brain with AD results in reduced metal uptake of 
Cu and Zn (Figure 3). This creates an accumulation of Cu and Zn over time due to the 
transporter mechanisms failing to distribute them around the brain. The synaptic Zn and Cu 
are being transported in the healthy brain by various mechanisms such as the amyloid-
precursor protein (APP) absorbing Zn and reducing metal accumulation (Figure 3). Duce et 
al. 2010 recognise that the appearance of free synaptic copper and zinc is maintained by a 




Figure 3 - Models of zinc and copper in the glutamatergic synapse in health and Alzheimer's disease (Duce, James et 
al, 2010) 
 
Decreased mitochondrial activity results in amyloid plaque deposition which inhibits the 
APPs ability to effectively decrease Zn concentrations and interferes with many other 
mechanisms in place to reduce metal accumulations. Therefore, recognising a trend in metal 
accumulations across transgenic mice brains with Alzheimer’s Disease (AD) can result in a 
better understanding of where these mechanisms are failing. The amyloid precursor protein is 
found most abundantly in the synapses of neurons and mutations of this protein could be 
implicated as a cause of amyloid-beta (AB) plaque build-up (Hardy et al. 2002). Maynard et 
al. (2002) found that an overexpression of the carboxyl-terminal fragment of the amyloid 
precursor protein, containing AB, results in significantly decreased levels of Cu and Fe in a 
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healthy transgenic mouse brain. Additionally, the study analysed the transgenic mouse brains 
of the Tg2576 model, which uses an overexpression of APP, and found Cu to be significantly 
reduced whereas Fe was not affected in the levels of metals in the brain prior to the formation 
of amyloid plaques. These results support the implication of APP and AB in maintaining 
metal homeostasis in the brain and that a failure and/or mutation of these proteins can result 
in metal accumulation or deficiency (Maynard et al. 2002). Copper is again implicated in 
APP trafficking in Acevedo et al. (2011) through promoting a ‘redistribution’ of APP from a 
perinuclear localisation to a wider distribution. Acevedo et al. (2011) found that Cu promoted 
an increase in cell surface APP by increasing its exocytosis and reducing its endocytosis 
respectively. Therefore, Cu heavily dictates APP’s locality and reach and accumulation of Cu 
could indicate increased localities of APP.  
The metal binding protein ‘metallothionein’ has been studied to provide a level of resistance 
to damaging concentrations of metals in the brain (Freedman et al. 1989). It binds with Cu to 
reduce the amount of detrimental free radicals and effectively balances the level of toxic 
metals in the brain. The success of this protein is controlled by the degree of metal exposure 
and therefore warrants the bio-mapping of metals in the brain to identify areas more at risk to 
metal exposure. Copper, Fe and Zn are intrinsically linked with plaque pathology and 
analysing the interaction of these metals with AB plaques will further lead to a greater 
understanding of AD. Lovell (1998) measured Cu, Fe and Zn in the rims and cores of senile 
plaques and in the neuropil of the amygdala of patients with AD and compared them with 
age-matched, healthy control patients using micro particle-induced X-ray emission (micro-
PIXE). Copper, Zn and Fe were found to be significantly increased in the rims of plaques in 
patients of AD when compared with the neuropil of patients with AD. Lovell et al. (1998) 
made the conclusion that Cu, Zn and Fe can accelerate the aggregation of the AB peptide. 
Therefore, mapping the distribution of metals in a brain may provide indications of where 
clusters of AB plaques will appear.  
Copper and Fe naturally increase with age and could dictate a starting point for AD to 
flourish. Squitti et al. (2002) suggests that serum Cu measurement may prove to be a 
diagnostic marker for AD. Recognising and mapping a normal distribution of metals in the 
brain as well as the distribution in affected brains, particularly Cu, Zn and Fe, could aid 
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studies and diagnostic markers in detecting and treating AD. An interesting area of study to 
be addressed is that of the difference in metal metabolism between the sexes due to the 
significantly higher incidence of AD in women (Maynard et al. 2006). It was found by 
Maynard et al. (2006) that women have lower Cu levels of men regardless of age and 
APP/AB expression (Maynard et al. 2006). The mice in this study are all female which 
allows the accumulations and/or deficiencies found to address specific mechanism failure to 
the largest cohort of AD sufferers. 
1.3 METAL DISTRIBUTION ASSOCIATED WITH AD 
Basun et al. (1990) conducted a study comparing the concentration of metals in cerebro-
spinal fluid (CSF) and blood in patients with Alzheimer’s and healthy volunteers. Zinc and 
Fe were only measured in blood and it was found that the Fe levels in the plasma of patients 
with AD were decreased when compared to their controls. This could be studied in the brain 
where deficiencies of Fe can be accounted to Fe-lacking plasma resulting in mechanism 
failure. In the CSF component it was discovered that Cu had increased in patients with 
Alzheimer’s when compared to their controls. This implicates metals as having direct links to 
Alzheimer’s disease due to their concentrations, in the brain and outside the brain, increasing 
or decreasing in patients with Alzheimer’s when compared to their healthy age-matched 
controls.  
Deibel et al. (1996), focused on the relationship between metals and Alzheimer’s disease 
through analysing Cu, Fe and Zn levels in five different brain regions (amygdala, 
hippocampus, inferior parietal lobule, superior and middle temporal gyri and cerebellum) in 
samples from patients with AD and age-matched controls using instrumental neutron 
activation analysis (INAA). Interestingly, a significant decrease in Cu concentrations was 
notable in the hippocampus’ of patients with AD. Zinc and Fe were significantly increased in 
the hippocampus of patients with AD which suggests the failure of a regulatory mechanism 
for Zn and Fe. The decrease in Cu can represent a transporter mechanism failure for Cu 
which could be resulting in accumulations elsewhere where the Cu isn’t being effectively 
transported to the hippocampus. The cerebellum was described to be minimally affected in 
AD and therefore no significant increase or decrease in metal levels was notable (Deibel et al. 
1996). Zinc is suggested by this study to play a more major role in senile plaque formation 
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than previously thought. This is supported by Kaden et al. (2011) where the role of Cu in AD 
is hailed as a positive one where the metal is said to lower AB production in cell culture 
systems through ‘promoting the non-amyloidogenic processing of APP’. Copper was 
analysed as a treatment in this study where the decline of AB plaques in CSF was noted in 
patients with AD treated with 8mg of Cu a day (Kaden et al. 2011). This further validates the 
notion that accumulations of Cu, rather than being an effect of AD, are the cause of 
detrimental metal mechanism failure not transporting Cu to the areas of the brain it needs to 
be. Therefore, using bio-maps to study the metal distribution in transgenic mice brains would 
be beneficial to further studies such as these.  
The severity of AD can be linked with increased metal dyshomeostasis in the brain and metal 
distributions can be studied to identify higher risk areas in a patient’s brain. Copper and Fe 
levels in plaques were studied by Bourassa et al. (2013) to be elevated to a higher degree in 
severe cases of AD. The study used three mouse models, two which showed 
neurodegeneration and one with less severe neurodegeneration. Copper levels were found to 
be increased by ~25% in the two models showing the higher degree of neurodegeneration 
which implicates increased Cu levels corresponding with greater severity of AD. Iron levels 
in the cortex were found to be increased as AD progressed in each of the three mouse models 
(Bourassa et al. 2013). This can indicate that Cu plays a more integral role in severe cases of 
AD than Fe and mapping the distribution of both metals will allow greater understanding of 
areas at higher risk of neurodegeneration. 
1.4 TREATMENTS FOR AD 
1.4.1 Metal-based treatments for AD 
Metal-based drug therapy or metal chelators have been explored through several journal 
articles as a means of treating AD. Ayton et al. (2015) recognises the potential for treatments 
directly targeting metals as a much more effective and time efficient solution. This introduces 
the notion that if CBD is proven to regulate metal distribution in the brain, without adverse 
effects on metal homeostasis, then it would both support its role as a treatment and further 
explore the understanding of metals in relation to AD. Hung et al. (2010) have proposed that 
treatment of the drug clioquinol to transgenic (Tg2576) mice expressing AD for 9 weeks 
resulted in significantly lower plaque pathology and total amyloid-beta protein when 
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compared to their controls. Accompanying the lower plaque pathology was a rise in the level 
of Cu which was hypothesised by Hung et al. (2009) to implicate Cu as being deficient in 
brains with AD. This direct link between Cu and AD could lead to alternative treatments 
which target Cu in the brain and attempt to increase the amount of the metal in the brain so as 
to return it to homeostasis. Therefore, the effect that treatment of CBD has on the amount and 
distribution of metals in the brain when compared to untreated controls will contribute and 
support the understanding between metals and their role in AD. 
1.4.2 Cannabidiol treatment 
The treatment of phytocannabinoid cannabidiol (CBD) as a therapeutic and preventative 
treatment for AD was studied by Cheng et al. (2014). Cannabidiol belongs to the group of 
molecules known as cannabinoids and is non-psychoactive and has proven in these studies to 
exhibit neuroprotective, anti-oxidant and anti-inflammatory effects and promotes 
neurogenesis. Cheng et al. (2014) found that chronic CBD treatment reversed cognitive 
deficits in transgenic APPxPS1 mice with AD such as associated impairments in social 
recognition and novel object recognition when being compared to healthy wild-type mice. It 
is important to note that no anxiety was exhibited by the treated mice as a result of a negative 
effect of the CBD. Another study by Cheng et al. (2014) exhibited CBD’s ability to prevent 
the development of a social recognition deficit in transgenic mice with AD without any 
impact on anxiety or associative learning. Therefore, the ability to treat and even prevent AD 
with CBD needs to be effectively studied to validate the research already achieved to promote 
its effectiveness. Metal distribution maps produced comparing the brains of transgenic mice 
with AD and transgenic mice with AD treated with CBD will also be crucial in noting if CBD 
has any effect on the distribution of metals in the brain. 
1.5 LASER ABLATION ICP-MS AND BIO-IMAGING 
The use of mapping in biomedical research is an increasingly popular and useful tool to 
highlight and define areas of interest. Metal distribution maps are extremely useful to define 
spatial trends of metals in biological samples. Bio imaging using laser ablation inductively 
coupled plasma mass spectrometry (LA-ICP-MS) offers comprehensive maps of distributions 
of metals in biological samples for various studies and is increasingly used in 
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bioaccumulation and bioavailability studies in plants, humans and animals (Becker et al. 
2014).  
Laser ablation ICP-MS as a method has become more widely utilised over the last decade in 
regards to bio-mapping metal distributions and was pioneered by Wang et al. (1994). The use 
of this method to produce an accurate representation of metal distribution in the brain is much 
more effective than the less specific bulk assay techniques previously utilised (Hare et al. 
2015). In the LA ICP-MS method a laser beam is produced and focused onto the biological 
sample to generate or ablate fine particles. These ablated particles are then transported via a 
mix of carrier gases (can be a mix of He, N2 and/or Ar) to the inductively coupled plasma. 
These particles experience extreme high temperatures in the plasma and subsequently convert 
to ions. These ions are passed through the mass spectrometer where they are detected and 
recorded as data into a csv file for further analysis. Matrix matched standards can be analysed 
at the same time as the biological sample to provide internal quantification standards. 
Imaging softwares such as Iolite and ImageEditor can then manipulate the data in the csv file 
to produce a bio map of intensity (cps) which can then further be quantified into a map of 
metal concentration (ppm). This method is extremely useful for accurately mapping metal 
distribution in the brain due to its sensitive detection limit in the low µg g-1 range (Becker et 
al. 2010). Becker et al. (2005) tested the ability of the LA ICP-MS method through using it to 
to analyse sections of human brain hippocampus. Inhomogenous distribution of P, S, Cu and 
Zn were analysed and the use of LA ICP-MS as a sensitive surface analytical technique was 
found to be a success. The use of matrix matched laboratory standards in the analysis of the 
hippocampal tissue was successfully used to quantify the elemental distribution in the region 
(Becker et al. 2005). Jackson et al. (2006) analysed metal distribution in 100µ thick rat brains 
and praised the ability of the LA ICP-MS method to collect multiple elements in a single 
session and therefore speed up the process of analysis.  
When compared to other methods such as secondary ion mass spectrometry (SIMS) and X-
ray fluorescence (XRF), LA ICP-MS stands out as being matrix insensitive and measures a 
wide range of concentrations with an impressive and improving spatial resolution of down to 
1µm (Becker et al, 2014). Hare et al. (2015) identifies that while the spatial resolution is 
improving it has done so relatively slowly since the original 1994 study by Wang et al. 
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Popescu et al. (2011) used X-ray fluorescence (XRF) to map and quantify metal distributions 
in the brain and highly praised LA ICP-MS as a more effective and powerful method due to 
its higher sensitivity 
The methods used to mount biological samples on the slide as well as the LA ICP-MS 
analytical method itself introduces large ranges of error where metals can be introduced or 
lost throughout the process (Hare et al. 2015). Therefore, the internal standards and 
calibrations in the LA ICP-MS method are extremely important to reduce the errors 
introduced in the sample preparation and analytical process and yield accurate 
quantifications. The calibration methods chosen are recognised by Hare et al. (2012) to be 
quite dynamic as each experiment using this method can experience errors coming from a 
multitude of sources. Thus, any single experiment using the LA ICP-MS method will need to 
recognise and address each error it is encountering and account for it using its own 
contextualised method of calibration and internal standards. Matrix-matched standards are 
recognised by Hare et al. (2013) as the most effective means for producing accurate, 
quantitative images using the LA ICP-MS method to produce metal distribution maps of 
biological samples. The matrix-matched standards will contain known concentrations of trace 
metals and through analysing these standards before and after a biological sample, a 
calibration curve can be produced to transform the counts per second analysed in LA ICP-MS 
to quantified concentrations of metals per pixel. Hare et al. (2013) tested how accurate these 
calibration curves prove to be and repeated 8-point calibration curves that were ‘reproducibly 
linear’ with correlation co-efficient ranging from ‘0.9874 (Mg) to 0.9991 (Sr)’ an example of 
which is in Figure 4. This study has solidified the accuracy of the calibration curve method 
and labelled the LA ICP-MS analysis as ‘suitable for quantifying most analytes in a sample 




Figure 4 - An example of counts per second or ‘signal intensity’ normalised by C are created into a calibration curve 









CHAPTER 2 – METHODOLOGY 
2.1 SAMPLE PREPARATION 
Thirty half (left side of sagittal section) female mice brains were received from Neuroscience 
Research Australia (NeuRA) with 16 being wild-type (WT) (8 for control and 8 with CBD 
treatment) and 14 being APPxPS1 AD affected (7 for control and 7 with CBD treatment) for 
comparison. Each mouse was on average 12 months old and weighing 25g at the time of 
sacrifice. Each brain was stored in a separate vial containing PFA and 30% sucrose for 
effective cryoprotection before cryosectioning. 
The vehicle solution used for the mice treated with cannabidiol consisted of powdered 
cannabidiol (CAS: 13956-29-1 THC Pharma GmbH, Frankfurt/Main, Germany) which was 
dissolved in equal amounts of Tween 80 (Sigma-Aldrich Co., St Louis, USA) and 100 % 
ethanol to the appropriate concentration and was diluted with 0.9 % sodium chloride (Long et 
al. 2010, 2012). Ethanol and Tween 80, a non-ionic detergent, comprised 10 % of the total 
volume. The drugs were delivered via i.p. route. 
2.2 CRYOSECTIONING PREPARATION 
Each of the left side half mice brains were stored in separate vials at ~3°C until preparation 
for cryosectioning. Four brains were prepared for cryosectioning at a time. Each brain would 
undergo the exact same preparations to achieve consistency. Tweezers were used to retrieve 
the brain out of the vial and the brain was laid immediately onto a paper towel to reduce 
excess sucrose. The left sagittal side of the brain is then positioned with tweezers where the 
flat and most central side of the brain is lying flat against a sample mould. OCT (freezing 
agent) is then used to cover the brain and fill the mould so the OCT is flush with the surface 
of the mould. Any bubbles resulting from this process are removed with tweezers. The 
sample moulds containing the brains are then taken to a cryostat (Leica, CM1950) where the 
chamber temperature is set to -15°C where the freezing agent will activate and completely 




The specimen holder temperature is set to -18°C, the width of cutting is set to 45µm and 
process set to ‘sectioning’. Each sample is positioned and sectioned in the exact same method 
to achieve consistency. Twelve blank gelatine coated slides are used for each sample with 4 
sections on each slide amounting to 48 sections per sample. The sample to be sectioned is 
oriented (Figure 6) and secured into the specimen holder to prevent slipping. The specimen 
holder is oriented as accurately as possible using mechanical adjustments. This part of the 
process has the potential to introduce quite a large error margin as the mechanical adjustment 
is undertaken solely by the user and their judgement of how flush the blade is with the 
sample. The limitations here are that a number of samples could have been cut at an angle to 
the blade and are therefore not a true representative cross-section when imaged. As a section 
is cut it will curl into itself unless a small paintbrush is used to keep it flat, therefore two 
small paintbrushes are kept inside the chamber for the entire process so they remain at the 
required temperature. The first sectioned cut is affixed onto the slide in the desired 
orientation (Figure 6). In this case, 4 sections are required on each of the 12 slides (Figure 7). 
Two initial slices are cut from the centre of the brain to remove excess OCT and enable 
sectioning from the fresh sample. The first section cut is positioned on the top right corner of 
Slide 1 and is the closest to the centre of the brain. The second section cut is positioned on the 
top right corner of Slide 2 and this process is repeated until Slide 12. The thirteenth section is 
positioned on Slide 1 on the top left corner, with the fourteenth being placed on the top left 
corner of Slide 2. This is repeated up to Slide 12 until the twenty fifth section which is placed 
on the bottom left corner of Slide 1. The twenty sixth section is placed on the bottom left 
corner of Slide 2 and this is repeated up to Slide 12 until the thirty seventh section which is 
placed on the bottom right corner of Slide 1. The thirty eighth section is positioned on the 
bottom right corner of Slide 2 and is repeated until the forty eighth section is placed on the 
bottom right corner of Slide 12. When each of the twelve slides have 4 sections affixed to 
them then the mouse brain sample is finished with the top right section being closest to the 
centre of the brain and the bottom left section being closest to the outer side of the brain 
(Figure 7). Section 5 was used for analysis in this project. All of slides with fresh sample are 




Figure 6 - The sagittal orientation of the sectioned slices is represented on the left and the regions of cerebellum and 
olfactory bulb highlight on the right. The hippocampal region is located internally in the central region of the brain. 
Images of the brain created using the software Brain Explorer 2 and then added to with drawing software. 
 
 
Figure 7 – Demonstrating the position of each slice in regards to the mouse brain for one sample. Section 5 was 




2.4 LASER ABLATION ICP-MS 
To measure metal concentration and distribution in each brain from the sectioned samples, 
laser ablation inductively coupled plasma mass spectrometry (LA ICP-MS) was used. In LA 
ICP-MS, a laser beam is produced and focused onto the biological sample to generate or 
ablate fine particles. These ablated particles are then transported via a mix of carrier gases He 
and N2 to the plasma torch. The sampled particles are excited in the plasma which causes 
them to undergo ionisation and then a mass spectrometer can detect the excited ions for 
analysis. In this study samples were ablated with a NWR193 ArF excimer laser ablation 
system and analysed using a Thermo iCAP-Q single-collector ICPMS. In a single session, 4 
samples were analysed with standards in-between each and a NIST, taking approximately 20 
hours. The 5th section was chosen from each sample to preserve experiment viability by 
reducing bias and enabling the comparison of sections from the same part of the brain. To 
allow accurate quantification, matrix-matched lamb brain standards with known 
concentrations are analysed before and after every sample to account for drift in plasma 
conditions in an individual session. The sections B, C, D, E, F and G with known metal 
concentrations were analysed using a maximum of 5 3mm merged lines through each 
individual section (Bottom slide; Figure 7). 
Each sample is set up with the exact same properties which were; laser spot size at 50µm, the 
scan speed at 200µm/s, the repetition rate at 20Hz and fluence at 0.8 J/cm². The lines created 
for the laser to follow are not merged to enable a comprehensive metal concentration map to 
be created in the further software used. Qtegra software is used to set up the experiment to 
run for the desired amount of time (calculated for each individual experiment using line 
length and laser speed) and the analytes 63Cu, 13C, 31P, 59Co, 66Zn and 57Fe selected to be 
collected. Helium is set at 650mL/s and turned on for approximately 10 minutes before the 
experiment is run. Argon gas is turned on for approximately 20 minutes before each 
experiment begins to purge the gas lines and eliminate any leftover remnants of previous 
experiments analytes in the lines. Nitrogen can be turned on after this purge for 
approximately 20 minutes before the experiment begins.  In the experiment created in Qtegra 
the acquisition parameters are set to ‘high’ resolution for analytes of interest (e.g. 63Cu, 66Zn 
and 57Fe) and total dwell time set to 0.25 seconds (equal to spot size divided by scan speed) 
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to reduce image distortion (Lear et al. 2012). The same rule applies to the dwell time as the 
resolution where analytes of greater interest and abundance are given higher dwell times. The 
dwell times for each isotope are as follows: 63Cu – 0.05 s, 13C – 0.03 s, 31P – 0.03 s, 59Co – 
0.04 s, 66Zn – 0.05 s and 57Fe – 0.05 s. The washout time for the laser is set to 30 s and the 
uptake time set to 15 s to give enough time for the laser to load before each line.  
The laser emission is turned on and an auto-tune using NIST612 is undertaken before running 
the experiment. NIST612 is a glass standard with known trace element concentrations used to 
tune and calibrate the laser and ICP-MS. The NIST612 is analysed using a straight line 
created running from the left side to the right side at an average 5mm length. The properties 
on the NIST612 line are as follows: scan speed at 5 µm/s, fluence at 5 J/cm2, repetition rate at 
5 Hz and spot size at 65 µm. The data is exported as a ‘Laser Data Reduction Export’ into a 
folder as ‘csv’ files for analysis in imaging software.  
2.5 IMAGING SOFTWARE AND DATA PROCESSING 
Following collection, an imaging software is required to produce metal distribution maps, and 
to convert isotope intensities (in counts per second) into metal concentrations (in ppm). 
ImageEditor is efficient imaging software that proves to be easily navigable and was 
therefore chosen to produce the metal concentration maps. 
The data is imported into ImageEditor as “comma: time,intensity” as well as “continuous 
data” to enable the software to turn 1 merged line of data from the laser into a 
comprehensible map. To create an initial intensity map for a given isotope, the isotope of 
interest is selected in the sidebar and the parameters set to velocity (200µm/s) and spot size 
(50µm). The parameters of ‘split’ (ablation time per line plus time to move between lines and 
change ‘DP’ to ‘s’) and ‘start x’ are unique to each sample. Rotation and reflection can be 
manipulated to display the brain image in the orientation of choice. The initial product is a 
map displaying intensity in counts per second (cps; Figure 8) and requires conversion into 




Figure 8 - An example of an initial map of laser counts per second for Cu for sample 234 created in ImageEditor. The 
x and y axis represent a given sample’s coordinate position. Coloured scale represents laser counts per second for Cu. 
 
The data acquired from the matrix-matched lamb brain standards can then be utilised to 
create a calibration curve for each element (Cu, Zn and Fe) and quantify the sample that was 
run between them. The standards are imported into ImageEditor as “comma: time,intensity” 
and do not need to be imported as “continuous data” due to it being necessary to retrieve the 
average from each of the 6 sections individually. Once imported the ‘select data’ tool in the 
‘Data Selection’ tab can be utilised to select the data within each of the 5 lines for each of the 
6 sections of the standard in relation to the isotope of interest (Figure 9). Once selected, this 





Figure 9 - An example of data from standards before selection for Cu for sample 234 in ImageEditor. The x and y 
axis represent a given sample’s coordinate position. Coloured scale represents laser counts per second for Cu. 
 
Using the average isotope intensities from the lamb brain standards against their known 
element concentrations, a calibration curve is produced for the quantification of a particular 
sample. Using the intercept and x-variable from each samples’ calibration curve, the maps of 
intensity can be transformed into a metal concentration map using the ‘Quantifier’ tool in 
ImageEditor (Figure 10). A decision was made to change the scale for all elements to a 




Figure 10 - An example of a quantified image for Cu for sample 234 in ImageEditor 
 
Normalisation to phosphorus (P) can also be implemented at this stage of data processing to 
account for high readings. After experimentation, it was decided that the quantified metal 
concentration map without normalisation to P was the most comprehensible and 
representative map. The quantified image with normalisation to P is seen in Figure 11 as 
detecting extremely low concentrations that were background metal levels and not relevant to 
the metal distribution in the brain itself. The quantified image without normalisation to P is 
seen in Figure 11 to be a much more representative map of metal distribution and when 
compared to the map of intensity. Therefore, without using normalisation to P, a quantified 
map for each samples’ Cu, Zn and Fe metal distribution was created totalling 90 maps. These 
metal distribution maps were used to identify trends of accumulations and deficiencies 




Figure 11 - An example of a quantified map of Cu ppm normalised to P, a quantified map of Cu ppm and an intensity 
map of 63Cu for sample 296 created in ImageEditor. The x and y axis represent the position of the given sample. 
2.6 SPATIAL ANALYSIS 
To extract the data values from regions of interest, such as the hippocampus and cerebellum, 
as well as extract total average concentrations, a method was devised using ArcGIS software 
(ESRI, ArcMap 10.2). ArcGIS was chosen due to the ease of the software to be utilised to 
select regions and extract data from them. The creation of a base brain map is necessary to 
effectively georeference each sample (Figure 12). The base brain map is given a scale and 
control points to produce a georeferenced image using the georeferencing tool. From this 





Figure 12 - An example of the brain map chosen to act as a base when referencing the bio maps in ArcGIS. Source: 
Allen Institute for Brain Science (2017) 
 
The data from each metal distribution map created in ImageEditor was exported as a ‘csv’ 
file and uploaded into ArcCatalog for manipulation using ArcGIS. Each Cu, Zn or Fe, file is 
converted into a shapefile from its XYZ table and then further converted into a raster dataset. 
These rasters can then be manipulated using the georeferencing tool and effectively ‘pinned’ 
down using control points onto the base brain map so that an individual samples area of 
interest of the brain, such as the hippocampus, can be aligned accurately with the base brain 
map (Figure 13). Due to the nature of the sample brains not always fitting perfectly over the 
base brain, each brain was referenced individually and has individual control points and 
might sit slightly differently over the base brain. The control points use a 1st order polynomial 
(affine) transformation and a least square fitting (LSF) algorithm to permanently match the 
control points to their new position. This least square fitting method determines a line of best 
fit where each ‘square’ is created using a mathematical function that squares the distance 
between a data point and the regression line. After each sample’s Cu, Zn and Fe metal 
distribution maps are referenced as close as possible to the base brain map it is now possible 




Figure 13 - An example of a referenced Cu concentration raster dataset for sample 298 in ArcGIS showing its control 
points from the georeferencing tool. The numbers correlate with each control point created to ‘pin’ it down to the 
base brain map. 
 
To extract data from specific areas of the brain, a new feature class is created as a polygon 
feature and used to outline the area of interest. This polygon directly overlies the area of 
interest when used with each individual sample and its corresponding metal concentration 
maps (Figure 14). Due to only one base polygon being used to overlay it, it is extremely 
important that each sample is referenced as close as possible to the area of interest, which 
means that other areas of the brain can warp. This step introduces a large margin of error due 
to only using one base polygon to overlay every Cu, Fe and Zn concentration maps when 
each individual sample can differ slightly. Due to the nature of a brain, it is impossible to 
perfectly align every sample so the error introduced in this step is necessary to give an 
indication of an as accurate as possible average concentration of regions in the brain. To 
extract the concentrations of the area of interest, the tool ‘extract values to a table’ is utilised 
with a polygon feature class for the selected area (e.g. hippocampus) and the raster dataset of 
an individual sample. From this data, the average concentration for the area of interest can be 
exported as a table into Excel and the average concentrations of the area of interest (e.g. 




Figure 14 - An example of a referenced Cu image for sample 298 and its hippocampal region polygon overlaying it in 
ArcGIS 
 
The initial average concentration values achieved using the ‘extract values to a table tool’ in 
ArcGIS had unusually small amounts of data points. After cross-referencing the classified 
colour scheme and corresponding value in ArcGIS for the hippocampal region with the data 
output from the tool it became apparent that the tool was not picking up on every data point. 
This was found to be due to the conversion of the data from a shapefile to a raster over-
complicating the process and causing the tool to extract only limited data points. Therefore, 
the data needed to be extracted from its original shapefile and a different tool utilised.  
The georeferenced raster image and base brain reference were employed again as a means of 
positioning the shapefile the correct way to extract from the nominated region accurately. To 
interpret the shapefile as the brain map, it was necessary to re-symbolise the image as 
‘quantities’ in relation to its ‘I’ value (intensity values). The ‘spatial adjustment tool’ was 
utilised to employ displacement tool links to reference the shapefile to the already referenced 
raster layer file. The polygon required for the area of interest then allowed selection of every 
data point within the polygon when overlain on the shapefile through the ‘selection’ tool 
(Figure 15). The selected data points could then be copied into an Excel sheet and accurate 
average concentrations calculated. The data extracted from ArcGIS was still in its intensity 
(cps) form and therefore each average needed to be further converted into concentration 
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(ppm) using the calibration curve produced previously for each samples’ Cu, Zn and Fe map 
respectively. This was repeated until every sample had an average concentration for the areas 
of hippocampus, cerebellum and whole brain for Cu, Zn and Fe. 
 
Figure 15 - An example of the referenced Cu shapefile and its selected region from the cerebellum polygon using the 




CHAPTER 3 – RESULTS AND DISCUSSION 
3.1 COPPER 
3.1.1 Copper in the whole brain 
Copper levels are known to be increased in areas of enhanced plaque pathology and therefore 
play a fundamental role in AD processes in the brain (Greenough et al. 2013). The Cu 
concentration in each sample’s whole brain was analysed to compare trends between the 
groups. Regions identified with increased Cu concentration can indicate regions of enhanced 
plaque pathology and AD processes.  
Average Cu concentrations for the whole brain were calculated for each of the 30 brains 
(Appendix 1). Following these calculations, the average value for each of the four groups was 
achieved (Table 1). Copper had an average concentration of 3.12 ± 0.95 ppm (2 STD. ERR.; 
n = 7) in an AD brain and 3.73 ± 1.42 ppm (2 STD. ERR.; n = 8) in a WT brain (Table 1). Cu 
concentrations in the whole brain of AD mice were higher 3.75 ± 0.79 ppm (2 STD. ERR.; n 
=7) when treated with CBD and increased in WT mice to 5.07 ± 1.99 ppm (2 STD. ERR.; n = 
8) when treated. The p values of each comparative group were calculated using an unpaired t 
test to compare the averages of one group against another which yielded no significant results 
apart from the comparative group of AD vs WT CBD (Table 2). The p value for this 
comparative group is indicative of a potential Cu deficiency in AD brains when compared to 
increased Cu concentrations in healthy, WT brains treated with CBD. An increase or decrease 
in Cu can be a direct result of regulatory mechanism failure such as in the case of the metal 
binding protein ‘metallothionein’ which binds with Cu to reduce the amount of detrimental 
free radicals in the brain (Freedman et al. 1989).  
Table 1 - Average Cu concentrations in whole brain for each group 
Group Mean (Cu ppm) Standard Deviation Standard Error n 
AD 3.12 0.95 0.36 7 
WT 3.73 1.42 0.50 8 
AD_CBD 3.75 0.79 0.30 7 
WT_CBD 5.07 1.99 0.70 8 
Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group); 
standard error of the mean - estimates variability between sample 
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Table 2 - The t test generated p value for each comparative group’s (vs) average Cu concentration in the whole brain 
Group (vs) p-value 
AD vs WT 0.35 
AD_CBD vs AD 0.20 
AD_CBD vs WT_CBD 0.13 
WT_CBD vs WT 0.14 
WT vs AD_CBD 0.97 
AD vs WT_CBD 0.04 
 
Copper concentrations in the whole brain across the 4 groups are shown to be deficient in the 
corpus callosum (Figure 16 and Figure 17; Appendix 4). The corpus callosum is the region of 
the brain that connects the two hemispheres and deficiency of Cu in this region can indicate 
the failure of Cu transporters in the brain. Transportation failure is seen more frequently in 
brains affected with AD such as the deficiency of the Cu transporting protein ceruloplasmin 
(Snaedel et al.1998). Apart from this one overarching trend between the groups, it is quite 




Figure 16 - The Cu concentration (coloured scale; in ppm) for the first three samples analysed in each group. The x and y axis represent a given sample’s coordinate position. AD 
represents untreated APPxPS1 mice ad AD CBD represents APPxPS1 mice treated with cannabidiol (CBD). WT represents untreated wild type, healthy mice and WT CBD 





Figure 17 - The distribution of Cu concentration (coloured scale; in ppm) for Sample 274 showing Cu deficiency in 
the corpus callosum (located approximately centrally in the square). The x and y axis represent coordinate position of 
the sample.  
 
Copper concentrations in the whole brain are lower in AD mice (Figure 16). The lower 
average Cu concentration in the brain for mice with AD explores the idea that Cu is deficient 
in an AD brain when compared to healthy, WT mice brains. The therapeutic role of metal 
chelators and treatments targeting more effective transportation and production of metals 
such as Cu could be studied to prove more effective when targeting and treating AD (Ayton 
et al. 2015). Kaden et al. (2011) found a decline in amyloid-beta (AB) plaques when treating 
transgenic mice with AD with Cu which further builds upon the idea that Cu could be used to 
promote wider metal distribution and metal homeostasis in an AD brain. Therefore, Cu could 
provide a therapeutic role in its interaction with AD processes. The decreased mitochondrial 
activity in a brain with AD leading to Cu and Zn accumulations noted in Duce et al. (2010) 
can also explain the lower average Cu concentration found in the AD brains. The 
accumulations of Cu and Zn in the glutamatergic synapse were caused by transporter 
mechanisms failing to distribute them around the brain which could result in an overall 
average lower concentration of the metals. This can explain the increased Cu concentration in 
the rims of plaques in patients with AD studied by Lovell et al. (1998) whilst also supporting 
the lower average Cu concentration in AD brains found in this study. The correlation of 
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increased Cu concentration and increased severity of AD studied in Bourassa et al. (2013) 
could also play a role in understanding the lower average Cu concentration in the AD mice. 
The severity of AD in the mice analysed in this study might not have reached the stage where 
Cu begins to increase. This is an interesting avenue for future studies to approach by 
comparing the metal distribution in the brains of AD and WT mice at different stages of AD.  
 
Figure 18 - Average Cu concentrations (ppm) in whole brain for each group 
 
Interestingly, CBD treatment results in an increase in the median Cu concentration in both 
AD and WT brains (Figure 18). CBD could be promoting higher Cu concentrations in the 
brain. Hung et al. (2009) found that increased Cu levels correlated with lower plaque 
pathology when treating AD brains with clioquinol therefore it is necessary to analyse plaque 
pathology in relation to CBD treatment to further support this idea. It is also interesting to 
note that treated and untreated AD brains had lower standard deviations when compared to 
treated and untreated WT brains (Table 1). This suggests that WT brains have a greater 
variability in average Cu concentration. Although the high variability seen in WT directly 
contrasts with the idea that healthy brains have an improved metal homeostasis. This is since 
metal homeostasis should translate to low standard deviation due to the more effectively 
regulated metal concentration. Therefore, the variability in Cu concentration in WT brains in 
AD    WT               AD CBD     WT CBD        
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this study could be due to errors influencing the results, such as metal contamination in the 
analytical process. The significant difference between the group of AD when compared to 
WT CBD using the unpaired t test further supports that metal levels in a healthy brain 
increase when treated with CBD. This is due to the trend of AD mice having a lower average 
concentration of Cu in the brain when compared to WT, healthy mice. Therefore, the 
deficient, AD brain, would be expected to be significantly different to a brain with increased 





3.1.2 Copper in the hippocampus 
The hippocampus is a region in the brain responsible for learning, memory and emotions and 
is directly affected in AD (Greenough et al. 2013). Enhanced plaque pathology is noted in the 
hippocampal region which raises interest in regards to the metal distribution also noted in the 
area. The trends in Cu concentration identified in the analysis will therefore be discussed to 
identify regions of interest for AD processes and in relation to CBD treatment. Average Cu 
concentrations for the hippocampus were calculated for each of the 30 brains (Appendix 1). 
Following these calculations, the average value for each of the four groups was achieved 
(Table 3). The average Cu concentration in the hippocampus for AD brains 6.39 ± 3.20 ppm 
(2 STD. ERR.; n = 7) was lower than the average for WT 8.65 ± 3.93 ppm (2 STD. ERR.; n = 
8). This supports the study by Deibel et al. (1996) that found Cu to be significantly decreased 
in the hippocampus of AD patients. 
Table 3 - Average Cu concentrations in hippocampus for each group 
Group Mean (Cu ppm) Standard Deviation Standard Error n 
AD 6.39 3.20 1.21 7 
WT 8.65 3.93 1.39 8 
AD_CBD 5.72 1.87 0.71 7 
WT_CBD 11.11 8.63 3.05 8 
Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group); 
standard error of the mean - estimates variability between sample 
 
The difference between the average concentrations seen in AD and WT in the hippocampus, 
although not statistically significant (Table 4), is further supporting the idea that Cu is 
deficient in an AD brain. The decreased average Cu concentration in the hippocampus can 
also be interpreted as transporter failure, which is also seen in the deficiency of the Cu 
transporting protein ceruloplasmin studied in AD patients (Snaedel et al. 1998). The failure of 
these transporter mechanisms could be resulting in Cu not being transported effectively to the 
hippocampus and accumulating elsewhere. Where exactly this Cu is accumulating is not 
abundantly clear in the AD brains when compared to the WT groups (Figure 16; Appendix 
4). Future studies can further explore Cu accumulations outside of the hippocampus to paint a 
clearer picture of where the transporter mechanisms begin failing. The brain of a patient with 
AD is studied in Ayton et al. (2013) to suffer from metallostasis which refers to the 
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interruption of metal trafficking mechanisms. Metallostasis is implicated in this study to 
result in the redistribution of metals, specifically Cu, Zn and Fe, into sporadic areas of the 
brain which disrupts metal ion homeostasis. The lower average Cu concentration in the 
hippocampus in AD brains when compared to WT brains analysed in this study could be a 
direct result of the metallostasis in the AD brain.  
Table 4 - The t test generated p value for each comparative group’s (vs) average Cu concentration in the 
hippocampus 
Group (vs) p-value 
AD vs WT 0.25 
AD_CBD vs AD 0.67 
AD_CBD vs WT_CBD 0.13 
WT_CBD vs WT 0.48 
WT vs AD_CBD 0.096 
AD vs WT_CBD 0.20 
 
The average variability of Cu concentration in the hippocampus for each group is studied to 
be more variable than the variability studied in the entire brain for each group (Table 3). This 
is interesting as it indicates that the Cu concentrations in each hippocampal region are highly 
variable which highlights a hotspot for metal mechanism function. This could be the result of 
each individual brain experiencing a different mechanism failure therefore the distribution of 
metals is caused to be extremely variable. This could also indicate that for a given brain, the 
average Cu concentration is relatively invariable unless you are focusing on specific regions, 
such as the hippocampus. Therefore, the distribution of Cu is seemingly regulated more 
efficiently; this could be due to the regulatory processes such as is seen when metals pass 
through the blood brain barrier (Duce et al. 2010).  
Cannabidiol treatment results in no statistically significant changes in the Cu concentrations 
in both AD and WT brains (Table 4). However, as a general trend, CBD treatment increases 
average Cu concentration in the hippocampus in WT brains from 8.65 ± 3.93 ppm (2 STD. 
ERR.; n = 8) (untreated) to 11.11 ± 8.63 ppm (2 STD. ERR.; n = 8) (treated). The increase in 
Cu concentration in brains treated with CBD when compared to untreated brains, while not 
statistically significant, is also seen in the whole brain analysis (Figure 19). Therefore, the 
trend for Cu concentration to increase in WT brains when treated with CBD is seen, not just 
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generally over the whole brain, but in specific regions such as the hippocampus. This trend 
could be pointing towards CBD treatment as therapeutic in the context of metal-based 
treatment studies across the whole brain as well as its specific compartments (Ayton et al. 
2015). Alternatively, CBD treatment could be proven to be toxic in the long-term in regards 
to its ability to increase the Cu concentration in otherwise healthy brains. This is seen in the 
increase of Cu concentration in WT brains when treated with CBD as disrupting the metal 
homeostasis that should be evident in healthy brains.   
 
Figure 19 - Average Cu concentrations (ppm) in the hippocampus for each group 
  
AD       WT              AD CBD    WT CBD        
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3.1.3 Copper in the cerebellum 
The cerebellum is known to display concentrated plaque pathology and is one of the regions 
in the brain directly affected in AD (Hardy, J. and D. J. Selkoe, 2002). Therefore, copper 
distribution in the cerebellum should identify areas of enhanced plaque pathology when it is 
accumulated. The analysed Cu distribution and subsequent average concentrations will be 
discussed in regards to AD processes. The cerebellum is identified to have sporadic degrees 
of enrichment across every brain in every group (Figure 16; Appendix 4). Cu deficiency in 
white matter and Cu enrichment in grey matter is noticeable in every brain in every group 
(Figure 16). The clear difference between Cu concentration in white and grey matter will be a 
useful tool when targeting mechanisms that need Cu to function in these regions of the 
cerebellum. Average Cu concentrations for the cerebellum were calculated for each of the 30 
brains (Appendix 1). Following these calculations, the average value for each of the four 
groups was achieved (Table 5). The average Cu concentration in the cerebellum of brains 
with AD was lower than the average concentration in WT brains (Figure 20). Therefore, for 
the whole brain, hippocampus and cerebellum it is evident that on average the Cu 




Figure 20 - Average Cu concentrations (ppm) in the cerebellum for each group 
 
Table 5 - Average Cu concentrations in the cerebellum for each group 
Group Mean (Cu ppm) Standard Deviation Standard Error n 
AD 4.40 1.08 0.41 7 
WT 5.82 1.72 0.61 8 
AD_CBD 5.50 1.91 0.72 7 
WT_CBD 6.96 2.81 0.99 8 
Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group); 
standard error of the mean - estimates variability between sample 
 
The cerebellum has a notably more significant p value between the two groups of AD and 
WT mice when compared to the whole brain and hippocampus Cu concentrations with a p 
value of 0.08 (Table 6). The lower Cu concentration in the cerebellum of AD brains can again 
be pointing towards an overall deficiency of Cu in the brains of patients with AD. This can 
suggest that metal specific treatments, such as metal chelators, would be a more efficient 
means of treating the disease (Hung et al. 2009).  
Cannabidiol treatment is again seen to increase the average Cu concentration in the 
cerebellum of both AD and WT brains. This could be indicative of the CBD treatment having 
AD      WT              AD CBD     WT CBD        
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a therapeutic effect on an AD brain by raising its Cu concentration. Contrastingly, it could be 
leading to a toxic effect on a WT brain by unbalancing metal homeostasis in regards to Cu. It 
is important to note that the average concentrations analysed for Cu in the cerebellum had the 
smallest standard deviations which suggests that Cu concentrations are less variable in the 
cerebellum. This could suggest that the cerebellum is more tightly regulated than the 
hippocampus and can therefore control its metal content more efficiently.  
Table 6 - The t test generated p value for each comparative group’s (vs) average Cu concentration in the cerebellum 
Group (vs) p-value 
AD vs WT 0.08 
AD_CBD vs AD 0.21 
AD_CBD vs WT_CBD 0.27 
WT_CBD vs WT 0.34 
WT vs AD_CBD 0.74 






3.2.1 Zinc in the whole brain 
Zinc is implicated in the formation of AB plaques and predicted to have a significantly 
increased average concentration in the AD mice brains compared to WT brains correlating 
with enhanced plaque pathology. In direct contrast to Cu, it is evident in the Zn whole brain 
metal distribution maps that the corpus callosum has an enriched Zn concentration across all 
samples (Figure 21 and Figure 22; Appendix 5). This enrichment of Zn in the corpus 
callosum is useful for future studies when looking at mechanisms in the brain requiring Zn. 
Zn is highly enriched in this region and therefore dictates a region where Zn is not being 
taken up by mechanisms resulting in accumulation (Duce et al. 2010).  Alternatively, the Zn 
enrichment of the corpus callosum region can indicate the high function of Zn transporter 
mechanisms. If it is representing effective Zn transporter function it could implicate Cu 






Figure 21 - The Zn concentration (coloured scale; in ppm) for the first three samples analysed in each group. The x and y axis represent a given sample’s coordinate position. AD 
represents untreated APPxPS1 mice ad AD CBD represents APPxPS1 mice treated with cannabidiol (CBD). WT represents untreated wild type, healthy mice and WT CBD 




Figure 22 - The distribution of Zn concentration (coloured scale; in ppm) for Sample 274 showing Zn enrichment in 
the corpus callosum (located approximately centrally in the square). The x and y axis represent coordinate position of 
the sample.   
 
Average Zn concentrations for the whole brain were calculated for each of the 30 brains 
(Appendix 3). Following these calculations, the average value for each of the four groups was 
achieved (Table 7). The Zn concentration in an AD brain is 2.29 ± 3.19 ppm (2 STD. ERR.; 
n= 7) which is 0.70 ppm lower than the average concentration of Zn in WT mice brains 
(Table 7). Large variability is evident in the Zn concentrations across all brains which is 
further supported by the lack of statistically significant p values for each comparative group 
(Table 8). This variability can be linked with the extremely low Zn concentrations analysed 
in the brains resulting in 11 brains giving an average concentration for the whole brain of 0 
ppm (Figure 23). This value of 0 ppm is defined as being below the detection limit of 0.085 
ppm. This could be a result of analytical error where metal levels were lost in sample 
preparation processes. Alternatively, Zn concentrations across the whole brain might be too 
low for a definitive average and could prove to be more effectively analysed within specific 
regions. Definitive Zn concentrations across the whole brain could be achieved through a 





Figure 23 - Average Zn concentrations (ppm) in whole brain for each group 
 
Table 7 - Average Zn concentrations in the whole brain for each group 
Group Mean (Zn ppm) Standard Deviation Standard Error n 
AD 2.29 3.19 1.21 7 
WT 2.99 3.74 1.32 8 
AD_CBD 4.87 5.23 1.98 7 
WT_CBD 5.13 6.44 2.28 8 
Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group); 
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Table 8 - The t test generated p value for each comparative group’s (vs) average Zn concentration in the whole brain 
Group (vs) p-value 
AD vs WT 0.71 
AD_CBD vs AD 0.28 
AD_CBD vs WT_CBD 0.93 
WT_CBD vs WT 0.43 
WT vs AD_CBD 0.43 
AD vs WT_CBD 0.31 
 
It is important to note that CBD treatment for both AD and WT brains increased the average 
Zn concentration for each samples’ whole brain. Cannabidiol treatment increased Zn 
concentration in an AD brain from 2.29 ± 3.19 ppm (2 STD. ERR.; n = 7) to 4.87 ± 5.23 ppm 
(2 STD. ERR.; n=7) and from 2.99 ± 3.74 ppm (2 STD. ERR.; n= 8) to 5.13 ± 6.44 ppm (2 
STD. ERR.; n=8) in WT brains. Higher Zn concentrations are implicated with enhanced 
plaque pathology and therefore the promotion of an increased Zn concentration when a 
healthy brain is treated with CBD could prove to be toxic (Tiiman et al. 2013). Essentially, 
the CBD treatment is ‘turning’ the average metal concentration in an otherwise healthy WT 
brain into a brain exhibiting metal concentration levels associated with AD. This could be 
further explored in future studies by larger sample groups of CBD treated mice and the 





3.2.2 Zinc in the hippocampus 
The hippocampus is an important region of the brain when studying AD due to its normal 
function being directly affected in the disease. Higher Zn concentrations are seen in areas of 
the brain with increased plaque pathology, such as the hippocampus, and it is therefore 
necessary to analyse the distribution of Zn in this region. Average Zn concentrations for the 
hippocampus were calculated for each of the 30 brains (Appendix 3). Following these 
calculations, the average value for each of the four groups was achieved (Table 9). 
Table 9 - Average Zn concentrations in the hippocampus for each group 
Group Mean (Zn ppm) Standard Deviation Standard Error n 
AD 2.29 3.66 1.38 7 
WT 3.97 4.06 1.44 8 
AD_CBD 6.26 7.29 2.76 7 
WT_CBD 4.47 5.07 1.79 8 
Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group); 
standard error of the mean - estimates variability between sample 
 
Zinc had low, almost undetectable levels in the whole brain resulting in values of 0ppm for 
the average concentration across the brain. This value of 0ppm is defined as being below the 
detection limit of 0.085ppm. This is again seen in the average Zn concentration in the 
hippocampus where the 0ppm values greatly influence the data extracted from ArcGIS, 
specifically the median (Figure 24). The inclusion of 0ppm values in the calculation of the 
average concentration for Zn in the hippocampus (Table 10) was compared to the p values 
generated when not including the 0ppm values (Table 11). The p values remained statistically 
insignificant across all comparative groups (Table 11) and the average Zn concentration in 
every group increased from the average concentrations including 0ppm by ~2ppm. Analysing 
the data without the values of 0ppm did not lead to any new emerging trends and the 
deductions taken from the values remained the same. Therefore, it was decided to examine 





Figure 24 - Average Zn concentrations (ppm) in hippocampus for each group 
 
Table 10 - The t test generated p value for each comparative group’s (vs) average Zn concentration in the 
hippocampus 
Group (vs) p-value 
AD vs WT 0.42 
AD_CBD vs AD 0.22 
AD_CBD vs WT_CBD 0.59 
WT_CBD vs WT 0.83 
WT vs AD_CBD 0.46 









Table 11 - The t test generated p value for each comparative group’s (vs) average Zn concentration in the 
hippocampus (not including values of 0 ppm) 
Group (vs) p-value 
AD vs WT 0.70 
AD_CBD vs AD 0.49 
AD_CBD vs WT_CBD 0.69 
WT_CBD vs WT 0.75 
WT vs AD_CBD 0.53 
AD vs WT_CBD 0.59 
 
The highest levels of Zn were analysed to be found in the hippocampus when analysing 
“normal” values for the brain (Ramos et al. 2014). Contrastingly, the average Zn 
concentration in the hippocampus of AD mice brains was slightly lower than the average 
concentration in WT brains. This directly conflicts with the study by Deibel et al. (1996) 
which found Zn to be significantly increased in the hippocampus of AD patients. This 
conflict could be due to the different method of instrumental neutron activation analysis 
(INAA) being utilised by Deibel et al. 1996 being more sensitive to Zn. The decrease in Zn 
concentration in the hippocampus could also be explained by the metallostasis found in AD 
patients studied by Ayton et al. 2013. The metallostasis evident in AD brains could be 
leading to the redistribution of Zn to other compartments of the brain. The variability of 
average Zn concentration in the hippocampus across all brains (Figure 21; Appendix 5) could 
also be explained by metallostasis in brains with AD. The redistribution of metals could lead 
to accumulations in any part of the brain, leading to no clear trend between groups. Future 
studies can further analyse why Zn concentrations are so variable in the hippocampus through 
further comparison with a larger sample size. The failure of transporter mechanisms to 
distribute Zn around the brain evident in AD could also be contributing to the lower average 
Zn concentration in the hippocampus of AD mice. The ability of the APP to absorb Zn and 
reduce metal accumulation in a healthy brain as studied by Duce et al. 2010 is diminished in 
an AD brain and leads to Zn accumulation. This could directly affect the Zn transporters 
ability to transport the metal effectively and could lead to deficient concentrations of Zn in 
the hippocampus.  
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Cannabidiol treatment to both AD and WT mice is seen to raise the average concentration of 
Zn in the hippocampus (Figure 24). However, the standard deviation and general variability 
of the average concentration for each brain treated with CBD was extremely high which is 
even visually evident in Figure 21. Therefore, further analysis with larger sample sizes is 
necessary to draw conclusions on the effect CBD treatment has on Zn concentration in the 
hippocampus.  
3.2.3 Zinc in the cerebellum 
The Zn concentration in the cerebellum is identified to directly contrast with white and grey 
matter enrichment/deficiency evident in the cerebellum for Cu (Figure 16 and Figure 21; 
Appendix 5). The enrichment of Cu in the cerebellum grey matter is correlated with a 
deficiency in Zn. Zinc is then enriched in cerebellum white matter which correlates with Cu 
deficiency in cerebellum white matter. This provides a useful tool for future studies when 
analysing mechanisms involved with metal distribution in the cerebellum.  
Average Zn concentrations for the cerebellum were calculated for each of the 30 brains 
(Appendix 3). Following these calculations, the average value for each of the four groups was 
achieved (Table 12). The average of Zn concentration in the cerebellum of mice with AD 
when compared with the brains of WT mice is not significantly different (Table 13). A very 
slight decrease in average Zn concentration in AD brains 2.75 ± 3.04 ppm (2 STD. ERR.; 
n=7) is evident when compared with WT concentrations 3.33 ± 3.55 ppm (2 STD. ERR.; 
n=8). This is supported by Deibel et al. (1996) which studied no significant increase or 
decrease in metal levels in the cerebellum. This can again be supported by the lower standard 
deviation values evident across each group for the cerebellum region conveying tighter metal 




Figure 25 - Average Zn concentrations (ppm) in the cerebellum for each group 
 
Table 12 - Average Zn concentrations in the cerebellum for each group 
Group Mean (Zn ppm) Standard Deviation Standard Error n 
AD 2.75 3.04 1.15 7 
WT 3.33 3.55 1.26 8 
AD_CBD 5.45 5.72 2.16 7 
WT_CBD 4.57 4.39 1.55 8 
Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group); 










Table 13 - The t test generated p value for each comparative group’s (vs) average Zn concentration in the 
hippocampus 
Group (vs) p-value 
AD vs WT 0.74 
AD_CBD vs AD 0.29 
AD_CBD vs WT_CBD 0.74 
WT_CBD vs WT 0.54 
WT vs AD_CBD 0.40 
AD vs WT_CBD 0.37 
 
A slight increase in Zn concentration in the cerebellum of CBD treated brains when 
compared to untreated brains is also evident (Figure 25). This increase is not statistically 
significant and paired with high variability between every brain unindicated by group (Table 
13). Future studies can further analyse this trend of increase Zn concentration in treated AD 





3.3.1 Iron in the whole brain 
Iron is also implicated in enhanced plaque pathology due to increased concentrations of the 
element analysed in such regions, such as the hippocampus and cerebellum. The analysis of 
Fe distribution across the brain is necessary to indicate regions with advanced plaque 
pathology in AD brains when compared to WT brains. The Fe distribution across the brains 
sampled in this study will be discussed in the context of AD processes as well as metal 
distribution trends post-CBD treatment. Average Fe concentrations for the whole brain were 
calculated for each of the 30 brains (Appendix 2). Following these calculations, the average 
value for each of the four groups was achieved (Table 14). 
Iron is identified to be enriched in the cerebellum and olfactory bulb across every samples’ 
metal concentration map (Figure 26; Appendix 6). It is apparent that the average Fe 
distribution across the 30 brains does not present a trend defining one group exclusively 
(Figure 26). This is supported for the whole brain where the average Fe concentration 
between AD mice and WT mice differs by the insignificant amount of 0.11ppm (Table 14). 
This suggests that the average Fe concentration in the whole brain does not significantly 
differ between AD and WT (Table 15). The average Fe concentration could significantly 
differ between specific regions, such as the hippocampus and cerebellum, which will be 





Figure 26 - The Fe concentration (coloured scale; in ppm) for the first three samples analysed in each group. The x and y axis represent a given sample’s coordinate position. AD 
represents untreated APPxPS1 mice ad AD CBD represents APPxPS1 mice treated with cannabidiol (CBD). WT represents untreated wild type, healthy mice and WT CBD 




Table 14 - Average Fe concentrations in the whole brain for each group 
Group Mean (Fe ppm) Standard Deviation Standard Error n 
AD 2.15 2.44 0.92 7 
WT 2.04 3.01 1.06 8 
AD_CBD 2.52 2.31 0.87 7 
WT_CBD 4.18 3.13 1.11 8 
Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group); 
standard error of the mean - estimates variability between sample 
 
Table 15 - The t test generated p value for each comparative group’s (vs) average Fe concentration in the whole brain 
Group (vs) p-value 
AD vs WT 0.94 
AD_CBD vs AD 0.78 
AD_CBD vs WT_CBD 0.27 
WT_CBD vs WT 0.19 
WT vs AD_CBD 0.74 
AD vs WT_CBD 0.19 
 
Treatment of CBD is analysed to increase the average Fe concentrations in the whole brain 
for both AD and WT (Figure 27). The average Fe concentration for untreated AD brains is 
analysed to be 2.15 ± 2.44 ppm (2 STD. ERR.; n=7) and increases to 2.52 ± 2.31 (2 STD. 
ERR.; n=7) when treated with CBD. This is a relatively insignificant increase but supports 
the general trend that CBD treatment will increase the Fe concentration in an AD brain. The 
average Fe concentration for untreated WT brains is analysed to be 2.04 ± 3.01 (2 STD. 
ERR.; n=8) which doubles to 4.18 ± 3.13 (2 STD. ERR.; n=8) when treated with CBD. This 
suggests a more significant increase in Fe concentration when otherwise healthy brains are 
treated with CBD. Therefore, for each metal intrinsically linked to AD (Cu, Fe, Zn), CBD 
results in an increase in average concentration. As discussed previously this could point to a 
beneficial therapeutic treatment resulting in higher concentrations of metals leading to metal 




Figure 27 - Average Fe concentrations (ppm) in whole brain for each group 
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3.3.2 Iron in the hippocampus 
It is necessary to analyse the distribution of Fe in the hippocampus in the context of AD 
processes due to the correlation of increased Fe concentration being evident in areas of 
increased plaque pathology in AD such as the hippocampus (Greenough et al. 2013). Iron is 
enriched in the hippocampal region across every sample (Figure 26; Appendix 6). Iron is also 
seen to have been the most affected by contamination with most samples being dotted with 
uncharacteristic and variable high concentrations. This could represent that Fe is more easily 
introduced in the analytical process and therefore future studies will need to address this to 
produce less contaminated results for Fe. These areas of contamination can be influencing the 
average concentrations and representative data (Figure 28). Average Fe concentrations for the 
hippocampus were calculated for each of the 30 brains (Appendix 2). Following these 
calculations, the average value for each of the four groups was achieved (Table 16). 
 
Figure 28 - Average Fe concentrations (ppm) in the hippocampus for each group 
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Table 16 - Average Fe concentrations in the hippocampus for each group 
Group Mean (Fe ppm) Standard Deviation Standard Error n 
AD 8.59 2.83 1.07 7 
WT 8.11 4.17 1.47 8 
AD_CBD 9.44 4.27 1.61 7 
WT_CBD 15.29 7.91 2.80 8 
Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group); 
standard error of the mean - estimates variability between sample 
 
Iron is implicated along with Cu and Zn to be enriched in areas of enhanced plaque 
pathology, such as the hippocampus (Lovell et al. 1998) and yet there is no significant 
increase or decrease in Fe concentrations in the hippocampus of an AD affected brain when 
compared to a WT brain (Table 17). This can suggest that levels of Fe are more tightly 
regulated in the hippocampus and Fe concentrations associated with AD could be 
experiencing accumulations or deficiencies elsewhere in the brain. Therefore, it can be 
interpreted that the average Fe concentration in the hippocampus is not closely linked to AD 
processes.  
Table 17 - The t test generated p value for each comparative group’s (vs) average Fe concentration in the 
hippocampus 
Group (vs) p-value 
AD vs WT 0.80 
AD_CBD vs AD 0.67 
AD_CBD vs WT_CBD 0.11 
WT_CBD vs WT 0.04 
WT vs AD_CBD 0.55 
AD vs WT_CBD 0.05 
 
Cannabidiol treatment is seen to significantly increase the concentration of Fe in the 
hippocampus in a WT brain where an untreated brain had an average Fe concentration of 8.11 
± 2.83 ppm (2 STD. ERR.; n=8) and a treated one increased to 15.29 ± 7.91 ppm (2 STD. 
ERR.; n=8). A higher concentration of Fe in the hippocampus is studied in Deibel et al. 
(1996) to be indicative of a brain with AD. This suggests that the trend of CBD treatment to 
significantly increase the Fe concentration in an otherwise healthy untreated WT brain is a 
toxic one. The treatment of CBD in this case is effectively altering a WT brain into a brain 
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that exhibits AD trends, in the context of the study by Deibel et al. (1996). This is shown by 
the increase in Fe concentration when WT brains are treated with CBD which represents 
enriched levels of Fe indicative of enhanced plaque pathology seen in AD (Greenough et al. 
2013). Further study is necessary to examine this trend with a larger sample size to determine 
the level of toxicity in WT mice treated with CBD in relation to Fe concentrations in the 
hippocampus. It could be that initial, short-term use of CBD is a therapeutic treatment to AD 
suffering brains to achieve metal ion homeostasis but a long-term treatment could prove to 
introduce toxic levels of metals into the brain.  
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3.3.3 Iron in the cerebellum 
Iron is analysed to have an overall trend of enrichment in the cerebellum across every brain in 
each group (Figure 26; Appendix 6). Average Fe concentrations for the cerebellum were 
calculated for each of the 30 brains (Appendix 2). Following these calculations, the average 
value for each of the four groups was achieved (Table 18). The Fe concentration in the 
cerebellum of an AD mouse brain 11.28 ± 3.83 ppm (2 STD. ERR.; n=7) when compared to a 
WT mouse brain 10.41 ± 2.89 ppm (2 STD. ERR.; n=8) is the only region of the brain 
analysed to have a slightly higher concentration (Figure 29). This increase is not statistically 
significant (Table 19) and is again supported by Deibel et al. (1996) which analysed no 
significant increase or decrease in metal concentration in the cerebellum of an AD patient 
when compared to healthy controls. However, due to it being the only region in the brain in 
this study to display a higher metal concentration in the AD brain it is an important trend. The 
increased Fe concentration in the cerebellum of the AD mice brains can be indicating a 
higher concentration of plaques and implicating Fe as a larger player in the formation of 
senile plaques. This is further supported by Bourassa et al. (2013) where Fe levels in plaques 




Figure 29 - Average Fe concentrations (ppm) in the cerebellum for each group 
 
Table 18 -  Average Fe concentrations in the cerebellum for each group 
Group Mean (Fe ppm) Standard Deviation Standard Error n 
AD 11.28 3.83 1.45 7 
WT 10.41 2.89 1.02 8 
AD_CBD 12.74 3.17 1.20 7 
WT_CBD 19.03 6.21 2.20 8 
Standard Deviation – population standard deviation (measure of uncertainty in regards to every sample in a given group); 





AD       WT              AD CBD       WT CBD        
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Table 19 - The t test generated p value for each comparative group’s (vs) average Fe concentration in the cerebellum 
Group (vs) p-value 
AD vs WT 0.62 
AD_CBD vs AD 0.45 
AD_CBD vs WT_CBD 0.03 
WT_CBD vs WT 0.0031 
WT vs AD_CBD 0.16 
AD vs WT_CBD 0.01 
 
Cannabidiol treatment to WT mouse brains was found to significantly increase Fe 
concentration in the cerebellum (Table 19). This is compared with an insignificant increase in 
Fe concentration in the cerebellum when AD brains are treated with CBD. This can further 
support the notion that short-term CBD treatment could have a therapeutic advantage to kick-
start metal-ion homeostasis in AD brains but long-term treatment on a recovering (closer to 
WT) brain could have a potentially toxic effect.  
3.4 GENERAL TRENDS 
The general trend of Cu, Zn and Fe concentrations in the whole brain, cerebellum and 
hippocampus regions in AD mouse brains compared to WT is a slight decrease in metal 
concentration in the AD brain. This is indicating that AD brains are deficient in metals which 
can be a direct result of mechanism failure such as a lack of ceruloplasmin resulting in 
interrupted Cu distribution in an AD brain (Snaedal et al. 1998).  
The most significant general trend in Cu, Zn and Fe concentrations in the whole brain, 
cerebellum and hippocampus regions is the increase of concentrations when AD and WT 
mice are treated with CBD. Every concentration in each of the three regions for every group 
experienced an increase when treated with CBD. As discussed, this could be indicative of a 
short-term therapeutic benefit of CBD in promoting metal ion homeostasis in affected brains. 
Alternatively, it is seen to increase the concentration of metals in WT, healthy brains to 
potentially toxic levels and therefore long-term use of CBD treatment could prove dangerous 
to brains after their metal levels reach homeostasis.  
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3.5 LIMITATIONS AND RECOMMENDATIONS 
The limitations of this study begin with the preparation of each sample brain in the 
cryosectioning process. When mounting the sample onto the specimen holder in the cryostat, 
the holder itself is oriented using mechanical adjustments completely independent on the user 
carrying it out. This introduces large margins of error as the mechanical adjustment is 
undertaken solely by the user and their judgement of how flush the blade is with the sample. 
The limitations here are that any number of samples could have been cut at an angle to the 
blade and are therefore not a true representative cross-section when imaged. This could also 
result in the bio maps displaying misleading accumulations or deficiencies, which would then 
result in inaccurate average concentrations when the data is extracted in ArcGIS. Therefore, 
future studies using the cryosectioning process should form a method to reduce the amount of 
mechanical adjustment necessary and try and substitute where possible.  
In the LA ICP-MS method there are limitations on sample contamination directly before, 
during and after analysis. Errors in the form of contamination of the sample through 
accidentally touching it directly and so on could result in misleading accumulations or 
deficiencies of metals in the bio maps and corresponding average concentrations of regions. 
These errors are relatively unavoidable but future studies should address them in their method 
to lower the risk of them occurring.  
In the method of extracting data from the regions of the cerebellum and hippocampus in 
ArcGIS there exist limitations that can be affecting the average concentrations studied. The 
use of only one polygon to highlight and select the data in the hippocampus and cerebellum 
for each of the 30 samples limits the data extracted due to possible variation of each sample. 
The samples are each georeferenced to a base brain which the polygon was created from but 
each brain did not ‘fit’ perfectly over the base brain and therefore data extraction could be 
taking from slightly different areas each time. In the time constraints of this study it was not 
feasible to create an individual polygon for each sample’s cerebellum and hippocampus but 
future studies can achieve this to provide more valid results.  
Further studies would benefit from using plaque staining methods on a similar section of 
brain and comparing that to the metal distribution map to more effectively draw conclusions 
about plaque pathology. 
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CHAPTER 4 – CONCLUSIONS 
The distribution of metals, specifically Cu, Fe and Zn, can indicate regions of interest in 
regards to AD processes. Metal concentration maps were produced to study metal distribution 
and provide further insight into their link with AD. The use of CBD as a treatment for AD 
was also studied in regards to metal distribution to shed light on the effect a treatment has on 
Cu, Fe and Zn. The LA ICP-MS method for analysis in this study was used to map the metal 
distribution of Cu, Fe and Zn in treated and untreated APPxPS1 and WT mice. The metal 
distribution maps created for each sample brain for Cu, Fe and Zn provided an important tool 
to identify general accumulation and deficiency trends in the brain. However, it was difficult 
to define a trend that was unique and indicative to one group for each metal. Therefore, using 
ArcGIS was found to be a beneficial method to extract data from specific regions to draw 
conclusions.  
The APPxPS1 mice were found to have on average lower Cu, Fe and Zn concentrations in the 
whole brain, cerebellum and hippocampus regions when compared to WT mice. Whilst not 
statistically significant, these results convey a general trend when comparing AD affected and 
WT brains. The only exception to this was the average Fe concentration in the cerebellum of 
APPxPS1 mice with AD found to be slightly higher when compared to WT mice brains. 
Overall, the APPxPS1 mice with AD were found to be deficient in metals when compared to 
WT which could be due to the failure of metal regulatory mechanisms in AD.  
Treatment of CBD to both APPxPS1 mice brains with AD and WT mice brains were found to 
generally increase the average concentration of metals in the brain. These results were mostly 
statistically significant but it highlights an interesting trend for future studies to analyse 
further. The concentration of Fe in the cerebellum was found to be significantly increased in 
treated WT mice brains when compared to untreated WT mice brains (p= 0.0031). The 
potential beneficial effect of CBD treatment is seen in the ability to increase average metal 
concentrations of Cu, Fe and Zn in a metal deficient AD brain. However, the potential for the 
CBD treatment to disrupt metal homeostasis and increase toxicity is seen in the dramatic 
increase in average metal concentration when otherwise healthy brains are treated. Therefore, 
a CBD treatment could prove therapeutic to AD affected brains but treatment of CBD to 
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healthy brains could have the potential for toxicity to arise and the chance for 
neurodegeneration to occur.  
Limitations in this study in sample preparation, analysis and post analysis data manipulation 
include the potential for error during mechanical adjustments in cryosectioning and operator 
error in ArcGIS when defining regions. Future studies should aim to address these limitations 
to produce more accurate results. This can include using an automatic adjustment process in 
cryosectioning to reduce error when cutting the sample and developing a more refined 
method in ArcGIS to define regions. Future studies benefit from the metal distribution maps 
created in this study through the ability to identify general trends of accumulation and 
deficiency to address in further research. The comparison of average metal concentrations 
found in this study will also prove beneficial to the further understanding of metals and their 
interaction with AD processes. The metal concentration maps can be utilised as an indicator 
of regions where metal regulatory mechanisms are failing in AD including transporters of 
metals found in the brain. Further studies would benefit from using plaque staining methods 
on a similar section of brain and comparing that to the metal distribution map to more 
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APPENDIX 1: AVERAGE CONCENTRATIONS – CU 
Cerebellum 
 
Sample Cu (ppm) Group 
234 9.4 WT 
235 3.01 AD 
243 8.06 WT_CBD 
247 4.62 WT_CBD 
248 4.55 AD_CBD 
256 6.11 AD 
257 6.18 WT 
258 4.54 AD 
259 10.83 WT_CBD 
260 5.43 WT 
261 3.18 WT 
262 6.11 WT 
263 9.51 AD_CBD 
264 5.99 WT_CBD 
265 4.66 AD_CBD 
267 5.39 AD_CBD 
270 11.35 WT_CBD 
274 5.5 AD 
280 5.21 WT 
281 4.59 AD_CBD 
282 4.18 WT_CBD 
283 3.77 AD_CBD 
290 3.63 AD 
291 5.39 WT 
292 5.67 WT 
296 6.01 AD_CBD 
297 5.73 WT_CBD 
298 4.9 WT_CBD 
299 4.17 AD 












Sample Cu (ppm) Group 
234 10.87 WT 
235 11.31 AD 
243 5.96 WT_CBD 
247 9.98 WT_CBD 
248 7.33 AD_CBD 
256 5.35 AD 
257 6.61 WT 
258 10.21 AD 
259 29.35 WT_CBD 
260 9.51 WT 
261 7.39 WT 
262 17.21 WT 
263 4.37 AD_CBD 
264 18.57 WT_CBD 
265 4.32 AD_CBD 
267 6.66 AD_CBD 
270 8.87 WT_CBD 
274 6.68 AD 
280 5.63 WT 
281 3.23 AD_CBD 
282 4.35 WT_CBD 
283 5.71 AD_CBD 
290 3.46 AD 
291 6.12 WT 
292 5.85 WT 
296 8.45 AD_CBD 
297 6 WT_CBD 
298 5.81 WT_CBD 
299 4.02 AD 













Sample Cu (ppm) Group 
234 2.2 WT 
235 1.51 AD 
243 3.29 WT_CBD 
247 4.51 WT_CBD 
248 3.62 AD_CBD 
256 3.6 AD 
257 2.73 WT 
258 3.77 AD 
259 6.48 WT_CBD 
260 3.07 WT 
261 2.37 WT 
262 6.11 WT 
263 4.61 AD_CBD 
264 5.89 WT_CBD 
265 3.39 AD_CBD 
267 3.81 AD_CBD 
270 9.11 WT_CBD 
274 4.36 AD 
280 3.85 WT 
281 2.56 AD_CBD 
282 3.46 WT_CBD 
283 3.36 AD_CBD 
290 2.39 AD 
291 4.24 WT 
292 5.3 WT 
296 4.89 AD_CBD 
297 4.14 WT_CBD 
298 3.67 WT_CBD 
299 3.37 AD 













APPENDIX 2: AVERAGE CONCENTRATIONS – FE 
Cerebellum 
 
Sample Fe (ppm) Group 
234 9.56 WT 
235 6.05 AD 
243 15.22 WT_CBD 
247 11.67 WT_CBD 
248 12.86 AD_CBD 
256 10.04 AD 
257 10.73 WT 
258 6.66 AD 
259 20.96 WT_CBD 
260 8.02 WT 
261 5.95 WT 
262 10.44 WT 
263 11.65 AD_CBD 
264 21.15 WT_CBD 
265 13.22 AD_CBD 
267 11.34 AD_CBD 
270 21.13 WT_CBD 
274 13.78 AD 
280 11.91 WT 
281 12.35 AD_CBD 
282 12.78 WT_CBD 
283 8.67 AD_CBD 
290 12.07 AD 
291 15.87 WT 
292 10.78 WT 
296 19.09 AD_CBD 
297 31.23 WT_CBD 
298 18.12 WT_CBD 
299 14.89 AD 












Sample Fe (ppm) Group 
234 5.82 WT 
235 8.21 AD 
243 19.69 WT_CBD 
247 9.22 WT_CBD 
248 8.96 AD_CBD 
256 5.6 AD 
257 3.87 WT 
258 6 AD 
259 31.03 WT_CBD 
260 3.89 WT 
261 6.58 WT 
262 9.05 WT 
263 5.93 AD_CBD 
264 6.13 WT_CBD 
265 11.07 AD_CBD 
267 8.56 AD_CBD 
270 18.96 WT_CBD 
274 11.55 AD 
280 9.1 WT 
281 8.6 AD_CBD 
282 10.21 WT_CBD 
283 4.97 AD_CBD 
290 9.66 AD 
291 16.66 WT 
292 9.92 WT 
296 17.98 AD_CBD 
297 14.95 WT_CBD 
298 12.09 WT_CBD 
299 6.38 AD 













Sample Fe (ppm) Group 
234 0 WT 
235 7.04 AD 
243 7.57 WT_CBD 
247 4.61 WT_CBD 
248 4.93 AD_CBD 
256 0 AD 
257 0 WT 
258 0 AD 
259 1.71 WT_CBD 
260 0 WT 
261 0 WT 
262 0.03 WT 
263 0 AD_CBD 
264 0 WT_CBD 
265 1.56 AD_CBD 
267 1.63 AD_CBD 
270 9.2 WT_CBD 
274 1.97 AD 
280 5.59 WT 
281 3.81 AD_CBD 
282 2.58 WT_CBD 
283 0 AD_CBD 
290 1.89 AD 
291 7.37 WT 
292 3.3 WT 
296 5.71 AD_CBD 
297 5.51 WT_CBD 
298 2.28 WT_CBD 
299 3.16 AD 













APPENDIX 3: AVERAGE CONCENTRATIONS – ZN 
Cerebellum 
 
Sample Zn (ppm) Group 
234 5.07 WT 
235 2.5 AD 
243 2.37 WT_CBD 
247 6.44 WT_CBD 
248 9.86 AD_CBD 
256 0 AD 
257 0 WT 
258 3.01 AD 
259 0 WT_CBD 
260 0 WT 
261 0 WT 
262 0.57 WT 
263 0 AD_CBD 
264 0 WT_CBD 
265 4.03 AD_CBD 
267 4.01 AD_CBD 
270 11.65 WT_CBD 
274 7.08 AD 
280 8.36 WT 
281 4.2 AD_CBD 
282 3.57 WT_CBD 
283 0 AD_CBD 
290 0 AD 
291 6.99 WT 
292 5.65 WT 
296 16.02 AD_CBD 
297 9.98 WT_CBD 
298 2.54 WT_CBD 
299 0.085 AD 











Sample Zn (ppm) Group 
234 9.93 WT 
235 0 AD 
243 0 WT_CBD 
247 6.63 WT_CBD 
248 7.48 AD_CBD 
256 0 AD 
257 0 WT 
258 0.81 AD 
259 0 WT_CBD 
260 0 WT 
261 0 WT 
262 1.6 WT 
263 0 AD_CBD 
264 0 WT_CBD 
265 3.82 AD_CBD 
267 3.65 AD_CBD 
270 13.69 WT_CBD 
274 7.16 AD 
280 8.04 WT 
281 7.63 AD_CBD 
282 3.31 WT_CBD 
283 0 AD_CBD 
290 0 AD 
291 6.94 WT 
292 5.26 WT 
296 21.24 AD_CBD 
297 9.55 WT_CBD 
298 2.6 WT_CBD 
299 0 AD 















Sample Zn (ppm) Group 
234 1.7 WT 
235 0 AD 
243 0.096 WT_CBD 
247 5.37 WT_CBD 
248 7.53 AD_CBD 
256 0 AD 
257 0 WT 
258 1.83 AD 
259 0 WT_CBD 
260 0 WT 
261 0 WT 
262 0 WT 
263 0 AD_CBD 
264 0 WT_CBD 
265 2.21 AD_CBD 
267 2.84 AD_CBD 
270 16.29 WT_CBD 
274 8.91 AD 
280 8.38 WT 
281 7 AD_CBD 
282 2.33 WT_CBD 
283 0 AD_CBD 
290 0 AD 
291 6.55 WT 
292 7.32 WT 
296 14.56 AD_CBD 
297 13.83 WT_CBD 
298 3.16 WT_CBD 
299 1.91 AD 




APPENDIX 4: METAL DISTRIBUTION MAPS - CU CONCENTRATIONS 
APPxPS1 brains (AD affected) 
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WT brains (healthy) 
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APPxPS1 (AD affected) brains treated with cannabidiol (CBD) 
248:       263: 
 
265:       267: 
 






WT (healthy) brains treated with CBD 
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259:       264: 
 













APPENDIX 5: METAL DISTRIBUTION MAPS - ZN CONCENTRATIONS 
APPxPS1 brains (AD affected) 
235:       256: 
 
258:       274: 
 












WT brains (healthy) 
234:       257: 
 
260:       261: 
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APPENDIX 6: METAL DISTRIBUTION MAPS - FE CONCENTRATIONS 
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APPENDIX 7: METHODOLOGY WORKFLOWS 
Cryosectioning preparation 
Each of the left sagittal side mice brains were stored in separate vials of 30% sucrose in a 
fridge environment at ~3°C until preparation for cryosectioning. Four brains could be 
completed per day averaging ~7 hours on the cryostat and therefore four brains were prepared 
for cryosectioning at a time. Each brain would undergo preparations as follows: 
1. Appropriate personal protection equipment (PPE) of standard gloves, lab gown, safety 
glasses and completely enclosed shoes are necessary before any preparations are undertaken 
in the PC3 laboratory. 
2. Tweezers are used to retrieve the brain out of the vial and the brain is laid 
immediately onto a paper towel to reduce excess sucrose. 
3. The left sagittal side of the brain is then positioned with tweezers where the flat and 
most central side of the brain is lying flat against a sample mould. 
4. OCT (freezing agent) is then used to cover the brain and fill the mould so the OCT is 
flush with the surface of the mould. Any bubbles resulting from this process are removed 
with tweezers extremely carefully. 
5. Vials previously containing the brains are disposed of in the appropriate biological 
hazard bin 
6. The sample moulds containing the brains are then taken to the cryostat where the 
chamber temperature is set to -15°C where the freezing agent will activate and completely 
freeze the samples for cryosectioning.  
7. A blank mould is filled with OCT to provide a base for the samples so that the blade 





With each sample now frozen in the cryostat chamber ready to be sectioned, the specimen 
holder temperature is set to -18°C, the width of cutting is set to 45µm and process set to 
‘sectioning’. The chamber light is turned on and while fixing the specimen to the specimen 
holder the blade guard must always be on and handle lock on when the blade is installed. 
Each sample is positioned and sectioned as follows: 
1. Appropriate personal protection equipment (PPE) of standard gloves, lab gown, safety 
glasses and completely enclosed shoes are necessary before any preparations are undertaken 
in the PC3 laboratory. 
2. Twelve blank gelatine coated slides are marked with the date, a number (from #1 
through to #12) and its sample number (eg #262) and positioned within reaching distance on 
top of the cryostat in sequence. Slides #1 - #6 will be used for laser ablation and slides #7 - 
#12 will be stored in a deep freezer for further studies.  
3. The blank mould is to be secured to the specimen base using a small amount of OCT 
to act as a base that will be used for every sample. Two small paintbrushes and one large 
paintbrush are to be found in the chamber and must be kept in the chamber at all times. 
4. The sample is to then be taken out of its mould and secured to the base of OCT 
(taking care of the orientation desired – in this case the cerebellum is on the right). 
5. The specimen base is then to be secured into the specimen holder (again taking care 
of orientation). 
6. The blade is then to be taken out of its holder and secured (extremely carefully) into 
place and the blade guard to be removed. 
7. To make sure the sample is flush with the blade, take the handle off lock and rotate it 
to move it forward (in 45µm widths) until the first slice of sample is achieved. If the cut has 
only been made on the left side, then the specimen holder needs to be moved further to the 
right and so on. Orientate the specimen holder as accurately as possible and then section a 
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couple of slices to make sure it is only the brain sample being cut and not any excess OCT on 
top of the sample (excess OCT around the sample can be cut away using a simple razor blade 
or similar). 
8. Once the sample is appropriately orientated the sections are ready for the slides. As a 
section is cut it will curl into itself unless a small paintbrush is used to keep it flat. Using one 
small paintbrush to keep it flat and another for positioning, fully cut the section and position 
it onto a side of the surface where it is easily able to be affixed to the corresponding slide. 
9. For the first section cut take the slide labelled #1 and affix it in an orientation desired 
(in this case 4 sections are required for each slide so section 1 is to be positioned on the top 
hand right corner of the slide, section 2 on the top hand left, section 3 on bottom hand right 
and section 4 on bottom hand left). 
10. Section 1 should be cut and affixed to each slide of #1 - #12 before section 2 is to be 
placed. 
11. When each of the twelve slides has 4 sections affixed to them then the sample is 
finished with section 1 being closest to the centre of the brain and section 4 being closest to 
the left side of the brain. 
12. The remaining sample, if any, is to be cut and disposed of with any other waste in the 
appropriate biological waste bin. 
13. When the last section is cut the chamber is to be completely cleaned and rid of any 
waste and the paintbrushes left in the chamber and the blade uninstalled and stored safely in 
its compartment next to the cryostat. The lock position is to be used on the handle and the 
chamber turned off. 
14. All of slides with fresh sample on them are to be stored in a fume hood overnight to 
dry and then stored in labelled sample boxes. The slides going to the deep freezer are to be 
promptly stored there. The slides to be ablated can be stored at room temperature until further 
analysing is required. 
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Laser ablation and ICP-MS 
After all the samples were cryosectioned and stored in the appropriately labelled sample 
boxes they were transported to the ICP-MS lab for analysing. In a singular session, 4 samples 
are able to be analysed with standards in-between each and a NIST, taking approximately 20 
hours. The 5th slide of each sample is to be used to preserve experiment viability by reducing 
bias. Each run will be set up as follows: 
1. Take out the stage and remove the holder from it and position on it the NIST (612), 
the fifth slide of four samples and the slide of lamb brain standards from which B, C, D, E, F 
and G will be used (necessary for quantification). Secure onto the holder with blu-tack. 
2. Replace the holder in the stage and check that the top of the samples are flush with the 
stage before inserting. Fasten the stage into place. 
3. Check that the correct cones (Ni high sensitivity cones) are installed and that the N₂ 
and He cylinders have at least ~500psi. Check the Ar tank as well and then turn on to build 
up pressure. 
4. Turn on the nitrogen, water chiller and laser and purge the lines with He for 10 
minutes and N₂ for 20 minutes before running the experiment. 
5. Open the program NWR and run ‘home stages’ 
6. Each line created for both standards and samples needs to be created with the 
properties of J/cm² = 0.8, spot size = 50µm, rep rate = 20Hz and scan speed of 200µm. 
7. For each sample, 5 lines of B, C, D, E, F and G will need to run before and after. 
Therefore, for a run of four samples there needs to be 5 x 5 lines created for each of the B, C, 
D, E, F and G standards. 
8. For each sample it is necessary to find the furthest left of the sample (x₁), the furthest 
right (x₂), the uppermost of the sample (y₁), the bottom of the sample (y₂) and the focus at 
either end of the sample (z₁ and z₂ respectively). 
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9. With these measurements the number of lines required for a sample can be 
determined from (y₂ - y₁)/0.05. The duration of the laser per line can be determined from (x₂ 
- x₁)/0.2. The time taken between lines can be measured by running the experiment without 
the laser enabled and using a timer to record how many seconds it takes from the end of the 
first line until the start of the second time. With every measurement recorded from above it is 
possible to determine the entire time necessary for the sample with the equation: (No. of 
lines)(Duration per line + time taken between lines) + 45.  
10. The NIST (612) will have a straight line created running from the left side to the right 
side. The properties on the NIST (612) line are as follows: Scan speed = 5 µm/sec, fluence = 
5 J/cm2, rep rate = 5 Hz, spot size = 65 µm 
11. Making sure the plasma is turned on, He at 650mL/s, N₂ purged and online, Tv2 cup 
calibrated and laser emission on, an autotune can be completed on the NIST (612).  
12. Once the autotune is successful a lab book can be set up. Individual lab books for 
each sample work best with standards run before each sample on each lab book and for that 
last sample standards are to be run before and after. Analytes to be collected are Cu, C, P, Co, 
Zn and Fe.  
13. The experiment can now run and will so for ~20 hours after pressing play.  
14. At the experiments end, data is to be exported into the appropriate folder and 




Imaging software and manipulation of data 
For standards: 
1. Import each file for the standards (in this study there were 6) as “time, intensity” and make 
sure the box for ‘continuous data (one file=one image) remains unchecked 
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2. Select the element of interest to work with 
3. For the first section of standards go to ‘select data’ and select the 5 boxes for each of the 
six lines of standard (corresponding to B – G) 
4. Click ‘export data’ and export as a .xlsx file 
5. In Excel you can now calculate the average of each section for the standards 
For sample: 
1. Import sample data file as comma “time, intensity” and check the box for ‘continuous 
data (one file=one image) 
2. Select the element of interest to work with 
3. Change all parameters to reflect the experiment including the individual split and start 
for each sample 
4. Enter in x variable and intercept derived from standards run before and after and click 
‘quantify’ 
5. Change scale to a maximum value that best reflects the concentration of the element 
chosen 
6. Change the rotation and reflection to desired position 
 
Extracting data using ArcGIS software as instructed by Alex Pescud 
(University of Wollongong) 
1. Turn on the “Spatial Adjustment” Tool bar 
2. Select “Spatial Adjustment”   
3. Within ArcMap, load in the following layers: 
a. Base Brain 
b. Referenced Raster dataset 
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c. Raw XY point data 
d. The section of the brain you are working with e.g. BBhippocampus 
4. You will now need to load in the raw XY data that was exported from the 
ImageEditor software. These files point files are not currently referenced.  
5. Re-symbolise the shapefile points to Quantities  
6. Spatially adjust the point file to the previously referenced raster 
7. Select the point shapefile and from the editor toolbar, select “Start Editing” 
8. Ignore the spatial reference messages 
9. Select the “New Displacement Tool Link”. 
10. Select equivalent points on the point shapefile that match the previously referenced 
raster file 
11. Click a corner on the point shapefile and then click on the corresponding corner of the 
raster 
12. Once you are happy with the links, select the “Spatial Adjustment” menu and click 
“Set Adjust Data…” 
13. Select all features and click “OK” 
14. Select the “Spatial Adjustment” menu again and click “Adjust”. The points should 
now match the spatial extent of the previously referenced raster. 
15. Click the “Selection” menu and select “Select By Location” option. 
16. Set the parameters to select all the points within the brain region of choice 
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17. Click “OK” 
18. The points should be selected (bright blue) 
19. From the “Editor Toolbar” select “Save Edits. 
20. Export selected values to a table. 
21. Right click the point layer > Selection > Copy Records For Selected Features 
22. Paste the values in to excel 
